



MCS Classicare 2025 Formulary 1 Prior Authorization Criteria

MCS Classicare MA-PD Group (HMO-POS), MCS Classicare Metro (HMO)

MCS Classicare requires you (or your physician) to get prior authorization for certain drugs. This means that you will need to get approval from MCS Classicare before you fill your prescriptions. If you don't get approval, MCS Classicare may not cover the drug.

MCS Classicare is an HMO plan subscribed by MCS Advantage, Inc.

ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Call 1.866.627.8183 (TTY: 1.866.627.8182).

ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.866.627.8183 (TTY: 1.866.627.8182).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.866.627.8183 (TTY: 1.866.627.8182)。

Last Updated: 09/26/2024

H5577_2920824_C

Prior Authorization Requirements

ABIRATERONE

Products Affected

- *abiraterone acetate oral tablet 250 mg, 500 mg*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Castration-resistant metastatic prostate cancer (CRPC), or B.) High risk, castration-sensitive metastatic prostate cancer (CSPC). For treatment of CRPC and CSPC, abiraterone will be used in combination with prednisone AND one of the following applies 1.) Used in combination with a gonadotropin-releasing hormone (GnRH) analog (e.g. leuprolide, triptorelin), OR 2) Patient has received bilateral orchiectomy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ACITRETIN

Products Affected

- *acitretin*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Severely impaired liver or kidney function, B.) Chronic abnormally elevated blood lipid values, or C.) Concomitant use of methotrexate or tetracyclines
Required Medical Information	Diagnosis of severe, recalcitrant psoriasis (including plaque, guttate, erythrodermic palmar- plantar and pustular) AND patient must have tried and failed, contraindication or intolerance to one formulary first line agent (e.g., Topical Corticosteroids (betamethasone, fluocinonide, desoximetasone), Topical Calcipotriene/Calcitriol, Topical Calcipotriene, OR Topical Tazarotene)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ACTEMRA-1

Products Affected

- ACTEMRA
- ACTEMRA ACTPEN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Giant cell arteritis, B.) Polyarticular juvenile idiopathic arthritis (PJIA) and patient has trial and failure or intolerance or contraindication to two preferred products, (i.e. Amjevita/Adalimumab-ADBIM, Enbrel), C.) Rheumatoid arthritis (RA) and patient has trial and failure or intolerance or contraindication to two preferred products, (i.e. Amjevita/Adalimumab-ADBIM, Enbrel, Rinvoq), D.) Systemic juvenile idiopathic arthritis (SJIA), or E.) Systemic sclerosis-associated interstitial lung disease
Age Restrictions	2 years of age and older
Prescriber Restrictions	For RA, pJIA: Rheumatologist
Coverage Duration	12 months
Other Criteria	Only for biologic therapy-naive patients: Physician's certification stating tuberculosis (TB) negative status or negative result of a TB detection test with a reading date less than 12 months before the start of therapy or chest x ray.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ACTIMMUNE

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic granulomatous disease for use in reducing the frequency and severity of serious infections, or B.) Severe, malignant osteopetrosis (SMO)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	B vs D determination required per CMS guidance
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ADALIMUMAB-ADB M

Products Affected

- *adalimumab-adbm (2 pen)*
- *adalimumab-adbm (2 syringe)*
subcutaneous prefilled syringe kit 10
mg/0.2ml, 20 mg/0.4ml, 40 mg/0.8ml
- *adalimumab-adbm(cd/uc/hs strt)*
- *adalimumab-adbm(ps/uv starter)*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, D.) Ankylosing spondylitis, E.) Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate, F.) Moderate to severe Crohn's disease in patients who have had an inadequate response to conventional therapy, G.) Moderate to severe ulcerative colitis in patients who have had an inadequate response to immunosuppressants (e.g. corticosteroids, azathioprine), H.) Non-infectious uveitis (including intermediate, posterior, and panuveitis), or I.) Moderate to severe hidradenitis suppurativa. For moderately to severely active rheumatoid arthritis: 1) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate (MTX), or corticosteroids. For active ankylosis spondylitis: patient has experienced an inadequate treatment response, intolerance, or contraindication to a non-steroidal anti-inflammatory drug(NSAID). For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) the patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).</p>

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Age Restrictions	For Juvenile Idiopathic Arthritis: 2 years of age or older. For Pediatric Crohn's disease: 6 years of age or older. For Hidradenitis Suppurativa: 12 years of age or older. For Uveitis: 2 years of age or older. For Ulcerative Colitis: 5 years of age or older. All other indications 18 years of age or older.
Prescriber Restrictions	1) For PsO and HS: Dermatologist, 2) For CD and UC: Gastroenterologist, 3) For Uveitis: Ophthalmologist, 4) For RA, PJIA, and AS: Rheumatologist, 5) For PsA: Dermatologist or Rheumatologist.
Coverage Duration	Plan Year
Other Criteria	Only for biologic therapy-naive patients: Physician's certification stating tuberculosis (TB) negative status or negative result of a TB detection test with a reading date less than 12 months before the start of therapy or chest x ray.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ADEMPAS

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

AFINITOR

Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Hypersensitivity to everolimus , or B.) Hypersensitivity to rapamycin derivatives (e.g. sirolimus)
Required Medical Information	Diagnosis of one of the following A.) Renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery, B.) Advanced hormone receptor-positive, HER2 negative breast cancer in postmenopausal women and taken in combination with exemestane, after failure with letrozole or anastrozole, C.) Progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin and disease is unresectable, locally advanced, or metastatic, D.) Pancreatic progressive neuroendocrine tumors and disease is unresectable, locally advanced, or metastatic, E.) Advanced renal cell carcinoma (RCC) after failure with sunitinib or sorafenib, F.) Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in patients who are not candidates for curative surgical resection
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

AKEEGA

Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) as detected on an FDA-approved test AND used in combination with prednisone
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ALECENSA

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ALOSETRON

Products Affected

- *alosetron hcl*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Constipation, B.) History of Chronic or severe constipation or sequelae from constipation, C.) History of ischemic colitis, intestinal obstruction, stricture, toxic megacolon, GI perforation, adhesions, diverticulitis, Crohn's disease, ulcerative colitis, D.) History of severe hepatic impairment, E.) History of impaired intestinal circulation, thrombophlebitis, or hypercoagulable state, or F.) Coadministration with flvoxamine
Required Medical Information	Diagnosis of irritable bowel syndrome, severe diarrhea-predominant
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ALUNBRIG

Products Affected

- ALUNBRIG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of anaplastic lymphoma kinase-positive (ALK) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

AMBRISENTAN

Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	Idiopathic pulmonary fibrosis (IPF), including those with pulmonary hypertension
Required Medical Information	Diagnosis of pulmonary arterial hypertension classified as WHO Group I, confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	12 months
Other Criteria	Continuation of therapy: patient is tolerating and responding to medication and has improved exercise capacity or a delay in clinical worsening.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

AMJEVITA

Products Affected

- AMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.4ML, 80 MG/0.8ML
- AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- AMJEVITA-PED 15KG TO <30KG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, D.) Ankylosing spondylitis, E.) Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate, F.) Moderate to severe Crohn's disease in patients who have had an inadequate response to conventional therapy, G.) Moderate to severe ulcerative colitis in patients who have had an inadequate response to immunosuppressants (e.g. corticosteroids, azathioprine), H.) Non-infectious uveitis (including intermediate, posterior, and panuveitis), or I.) Moderate to severe hidradenitis suppurativa. For moderately to severely active rheumatoid arthritis: 1) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate (MTX), or corticosteroids. For active ankylosing spondylitis: patient has experienced an inadequate treatment response, intolerance, or contraindication to a non-steroidal anti-inflammatory drug(NSAID). For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) the patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).</p>

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Age Restrictions	For Juvenile Idiopathic Arthritis: 2 years of age or older. For Pediatric Crohn's disease: 6 years of age or older. For Hidradenitis Suppurativa: 12 years of age or older. For Uveitis: 2 years of age or older. For Ulcerative Colitis: 5 years of age or older. All other indications 18 years of age or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Only for biologic therapy-naive patients: Physician's certification stating tuberculosis (TB) negative status or negative result of a TB detection test with a reading date less than 12 months before the start of therapy or chest x ray.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

APTIOM

Products Affected

- APTIOM

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of partial-onset seizures
Age Restrictions	4 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ARCALYST

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ARIKAYCE

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	Known sensitivity to any aminoglycoside
Required Medical Information	Diagnosis of pulmonary Mycobacterium avium complex (MAC) infection and used as part of a combination antibacterial regimen in treatment refractory patients (greater than 6 months of a multidrug background regimen)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist or pulmonologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ATYPICALS

Products Affected

- CAPLYTA
- FANAPT
- FANAPT TITRATION PACK
- LYBALVI
- REXULTI
- SECUADO
- VERSACLOZ
- VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

AUGTYRO

Products Affected

- AUGTYRO

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

AUSTEDO

Products Affected

- AUSTEDO
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE THERAPY PACK 12 & 18 & 24 & 30 MG, 6 & 12 & 24 MG

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Suicidal ideation and/or untreated or inadequately treated depression in a patient with Huntington's Disease, B.) Hepatic impairment, C.) Concomitant use of MAOIs, reserpine, tetrabenazine, or valbenazine
Required Medical Information	Diagnosis of one of the following A.) Chorea associated with Huntington's disease (Huntington's chorea), or B.) Tardive dyskinesia
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or psychiatrist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

AUVELITY

Products Affected

- AUVELITY

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

AYVAKIT

Products Affected

- AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Unresectable or metastatic gastrointestinal stromal tumor, with a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations, B.) Advanced Systemic Mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SMAHN), or mast cell leukemia (MCL), and platelet count of at least 50,000/mcL, or C.) Indolent systemic mastocytosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, allergist, or immunologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BALVERSA

Products Affected

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BANZEL

Products Affected

- *rufinamide oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Familial Short QT Syndrome
Required Medical Information	Diagnosis of seizures associated with Lennox-Gastaut syndrome
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BENLYSTA

Products Affected

- BENLYSTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Active, autoantibody-positive, system lupus erythematosus (SLE), or B.) Active lupus nephritis and patient is receiving standard therapy (corticosteroids, antimalarials, NSAIDs, immunosuppressives)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist or rheumatologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BESREMI

Products Affected

- BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Existence of, or history of severe psychiatric disorders (severe depression, suicidal ideation, or suicide attempt), B.) Hypersensitivity to interferons including interferon alfa-2b or excipients, C.) Hepatic impairment (Child-Pugh B or C), D.) History or presence of active serious or untreated autoimmune disease, or E.) Immunosuppressed transplant recipients
Required Medical Information	Diagnosis of polycythemia vera
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BEXAROTENE GEL

Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of primary cutaneous T-cell lymphoma (CTCL Stage 1A/1B) and patient had an inadequate response, is intolerant to, or has a contraindication to at least one prior systemic therapy (e.g., corticosteroids) indicated for cutaneous manifestations of CTCL
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BEXAROTENE ORAL

Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cutaneous T-cell lymphoma (CTCL) and patient is not a candidate for or had an inadequate response, is intolerant to, or has a contraindication to at least one prior systemic therapy (e.g., corticosteroids) for cutaneous manifestations of CTCL
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, hematologist, or dermatologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BOSENTAN

Products Affected

- *bosentan*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant cyclosporine A or glyburide therapy
Required Medical Information	Diagnosis of pulmonary arterial hypertension (WHO Group I) and patient has New York Heart Association (NYHA) Functional Class II-IV, confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e. g., patient is frail, elderly, etc.)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	Initial: 6 months, Renewal: Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BOSULIF

Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or inadequate response to prior therapy, or B.) Newly diagnosed chronic phase Philadelphia chromosome-positive (Ph+) CML
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BRAFTOVI

Products Affected

- BRAFTOVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) unresectable or metastatic melanoma with documented BRAF V600E or V600K mutation as detected by a FDA-approved test and used in combination with binimetinib, B.) metastatic colorectal cancer with documented BRAF V600E mutation as detected by a FDA-approved test, patient has received prior therapy, and braftovi used in combination with cetuximab, or C.) Metastatic non-small cell lung cancer with a BRAF V600E mutation as detected by an FDA-approved test and used in combination with binimetinib
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BRIVIACT

Products Affected

- BRIVIACT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of partial-onset seizures, member must have history of inadequate response, contraindication, or intolerance to levetiracetam prior to approval.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BRONCHITOL

Products Affected

- BRONCHITOL

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

BRUKINSA

Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following: A.) mantle cell lymphoma (MCL) and patient has received at least one prior therapy, B.) Treatment of adult patients with Waldenstrom macroglobulinemia, C.) Treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen (e.g., rituximab, obinutuzumab, ofatumumab), D.) Chronic lymphocytic leukemia, E.) Small lymphocytic lymphoma, or F.) Relapsed or refractory follicular lymphoma, in combination with obinutuzumab, after 2 or more lines of systemic therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CABOMETYX

Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma, B.) Advanced hepatocellular carcinoma (HCC) and patient has been previously treated with sorafenib, C.) Advanced renal cell carcinoma and used as first line treatment in combination with nivolumab or D.) treatment of adults and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following VEGFR-targeted therapy (e.g., Axitinib, Lenvatinib, Pazopanib, Sorafenib, Sunitinib, vandetanib) and who are radioactive iodine-refractory or ineligible
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CALQUENCE

Products Affected

- CALQUENCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Mantle cell lymphoma (MCL) and patient has received at least 1 prior therapy, B.) Chronic lymphocytic leukemia (CLL), or C.) Small lymphocytic lymphoma (SLL)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CAMZYOS

Products Affected

- CAMZYOS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) in adult patients
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CAPRELSA

Products Affected

- CAPRELSA ORAL TABLET 100 MG,
300 MG

PA Criteria	Criteria Details
Exclusion Criteria	Congenital long QT syndrome
Required Medical Information	Diagnosis of metastatic or unresectable locally advanced medullary thyroid cancer (MTC) AND disease is symptomatic or progressive
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CARGLUMIC ACID

Products Affected

- *carglumic acid*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) N-acetyl glutamate synthase (NAGS) deficiency (confirmed by appropriate genetic testing) with acute or chronic hyperammonemia, or B.) Propionic or methylmalonic acidemia with acute hyperammonemia
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CAYSTON

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CIMZIA-1

Products Affected

- CIMZIA
- CIMZIA (2 SYRINGE)

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CLOBAZAM

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of seizures associated with Lennox-Gastaut syndrome
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CNS STIMULANTS

Products Affected

- *armodafinil*
- *modafinil*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Obstructive sleep apnea (OSA) confirmed by sleep lab evaluation, B.) Narcolepsy confirmed by sleep lab evaluation, or C.) Shift work disorder (SWD)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

COMETRIQ

Products Affected

- COMETRIQ (100 MG DAILY DOSE)
- COMETRIQ (60 MG DAILY DOSE)
- COMETRIQ (140 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of progressive, metastatic medullary thyroid cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

COPIKTRA

Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsed or refractory chronic lymphocytic leukemia (CLL), or B.) Relapsed or refractory small lymphocytic lymphoma (SLL). For CLL or SLL, the patient must have history of at least 2 prior therapies
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CORLANOR

Products Affected

- CORLANOR

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Decompensated acute heart failure, B.) hypotension (i.e. blood pressure less than 90/50 mmHg), C.) sick sinus syndrome or sinoatrial block or 3rd degree AV block (unless a functioning demand pacemaker is present), D.) bradycardia (i.e., resting heart rate less than 60 bpm prior to treatment), E.) Severe hepatic impairment (Child-Pugh C), F.) Pacemaker dependent (heart rate maintained exclusively by the pacemaker), G.) Concomitant use of strong CYP3A4 inhibitors
Required Medical Information	Diagnosis of one of the following A.) Adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction 35% or less, who are in sinus rhythm with resting heart rate 70 beats per minute or more and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use, or B.) Pediatric patients with stable, symptomatic heart failure due to dilated cardiomyopathy and are in sinus rhythm with an elevated heart rate
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

COSENTYX

Products Affected

- COSENTYX
- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX UNOREADY

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

COTELLIC

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.)unresectable or metastatic malignant melanoma with BRAF V600E OR V600K mutation, and documentation of combination therapy with vemurafenib (Zelboraf), or B.) Histiocytic neoplasms
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

CYSTAGON

Products Affected

- CYSTAGON

PA Criteria	Criteria Details
Exclusion Criteria	Known serious hypersensitivity to penicillamine or cysteamine
Required Medical Information	Diagnosis of nephropathic cystinosis confirmed by the presence of increased cystine concentration in leukocytes or by genetic testing
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DALFAMPRIDINE

Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) History of seizure. B.) Moderate or severe renal impairment (creatinine clearance less than or equal to 50 mL/minute)
Required Medical Information	Diagnosis of multiple sclerosis and patient must demonstrate sustained walking impairment, but with the ability to walk 25 feet (with or without assistance) prior to starting dalfampridine
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DAURISMO

Products Affected

- DAURISMO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of newly diagnosed acute myeloid leukemia (AML) and used in combination with cytarabine in patients 75 years of age or older OR in patients that have comorbidities that preclude use of intensive induction chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an Oncologist or Hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DAYBUE

Products Affected

- DAYBUE

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DEFERASIROX

Products Affected

- *deferasirox*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Creatinine clearance less than 40 mL/min, B.) Poor performance status, C.) Platelet count less than 50 x 10 ⁹ /L, D.) Advanced malignancy, E.) High-risk myelodysplastic syndrome (MDS)
Required Medical Information	Diagnosis of one of the following A.) Chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes who have liver iron concentrations of at least 5 mg Fe/g dry weight AND serum ferritin level greater than 300 mcg/L, or B.) Chronic iron overload due to blood transfusions (transfusion hemosiderosis) as evidenced by transfusion of at least 100 mL/kg packed red blood cells AND serum ferritin level greater than 1000 mcg/L
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DEFERIPRONE

Products Affected

- *deferiprone*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) Diagnosis of transfusional iron overload due to thalassemia syndromes, sickle cell disease, or other anemias 2.) failure to current chelation therapy (e.g., deferoxamine)
Age Restrictions	8 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DIACOMIT

Products Affected

- DIACOMIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of severe myoclonic epilepsy in infancy (Dravet syndrome) in patients taking clobazam
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DICLOFENAC PATCH

Products Affected

- *diclofenac epolamine*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of acute mild to moderate pain due to minor strains, sprains and contusions
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	3 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DIMETHYL FUMARATE

Products Affected

- *dimethyl fumarate*
- *dimethyl fumarate starter pack*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DRONABINOL

Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Exclusion Criteria	Sesame oil hypersensitivity
Required Medical Information	Diagnosis of one of the following A.) Anorexia associated to AIDS, or B.) Chemotherapy-induced nausea and vomiting
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	B vs D determination required per CMS guidance
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DROXIDOPA

Products Affected

- *droxidopa*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (e.g., Parkinson disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Initial: 1 month, Renewal: 3 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

DUPIXENT

Products Affected

- DUPIXENT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>For atopic dermatitis (AD), initial therapy: 1) Patient has moderate-to-severe disease, AND 2) Patient has had an inadequate treatment response to either a topical corticosteroid or a topical calcineurin inhibitor, OR topical corticosteroids and topical calcineurin inhibitors are not advisable for the patient. For oral corticosteroid dependent asthma, initial therapy: Patient has inadequate asthma control despite current treatment with both of the following medications: 1) High-dose inhaled corticosteroid AND 2) Additional controller (i.e., long acting beta2-agonist, long-acting, muscarinic antagonist, leukotriene modifier, or sustained-release theophylline) unless patient has an intolerance or contraindication to such therapies. For moderate-to-severe asthma, initial therapy: Patient has a baseline blood eosinophil count of at least 150 cells per microliter and their asthma remains inadequately controlled despite current treatment with both of the following medications: 1) Medium-to-high-dose inhaled corticosteroid, AND 2) Additional controller (i.e., long acting beta2-agonist, long-acting muscarinic antagonist, leukotriene modifier, or sustained-release theophylline) unless patient has an intolerance or contraindication to such therapies. For asthma, continuation of therapy: Asthma control has improved on treatment with the requested drug, as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations or a reduction in the daily maintenance oral corticosteroid dose. For chronic rhinosinusitis with nasal polyposis (CRSwNP): 1) The requested drug is used as add-on maintenance treatment, AND 2) Patient has experienced an inadequate treatment response to fluticasone. For Eosinophilic esophagitis failure, intolerance or contraindication to PPIs</p>
Age Restrictions	None

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Prescriber Restrictions	Prescribed by or in consultation with an allergist, dermatologist, gastroenterologist, immunologist, otolaryngologist, pulmonologist, or rheumatologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria
MCS Classicare Formulary 1 - Formulary ID: 25509
Effective date: 01/01/2025 Last Updated: 09/26/2024

EMGALITY-1-2

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic or episodic migraine disorder and patient has documented trial, inadequate response, or contraindication to at least 2 generic formulary drugs used for migraine prevention (i.e., propranolol, topiramate, divalproex, timolol), or B.) Episodic cluster headache
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

EMSAM

Products Affected

- EMSAM

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant use with any of the following: SSRIs, SNRIs, clomipramine, imipramine, meperidine, tramadol, methadone, pentazocine, propoxyphene, dextromethorphan, carbamazepine, or B.) Pheochromocytoma
Required Medical Information	Diagnosis of major depressive disorder and patient had trial of at least 2 generic oral antidepressants from differing classes (at least one should be from the following list: selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, mirtazapine, or bupropion unless contraindicated), unless unable to take any oral medication AND Patient had an adequate washout period (for patients previously on agents requiring a washout period)
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ENBREL

Products Affected

- ENBREL
- ENBREL SURECLICK
- ENBREL MINI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, D.) Ankylosing spondylitis, or E.) Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy. For moderately to severely active rheumatoid arthritis: 1) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate (MTX), or corticosteroids. For active ankylosing spondylitis: patient has experienced an inadequate treatment response, intolerance, or contraindication to a non-steroidal anti-inflammatory drug(NSAID). For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) the patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).</p>
Age Restrictions	2 years of age for JIA and PsA, and 4 years of age for PsO
Prescriber Restrictions	1) For RA, PJIA, AS: Rheumatologist, 2) For PsA: Dermatologist or Rheumatologist, 3) For PsO: Dermatologist.
Coverage Duration	Plan Year

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Other Criteria	Only for biologic therapy-naive patients: Physician's certification stating tuberculosis (TB) negative status or negative result of a TB detection test with a reading date less than 12 months before the start of therapy or chest x ray.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria
MCS Classicare Formulary 1 - Formulary ID: 25509
Effective date: 01/01/2025 Last Updated: 09/26/2024

ENSPRYNG

Products Affected

- ENSPRYNG

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Active Hepatitis B infection, or B.) Active or untreated latent tuberculosis
Required Medical Information	Diagnosis of neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody positive
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, immunologist, or ophthalmologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

EPIDIOLEX

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Lennox-Gastaut syndrome, B.) Severe myoclonic epilepsy in infancy (Dravet syndrome), or C.) Seizures associated with tuberous sclerosis complex (TSC)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

EPOETIN THERAPY

Products Affected

- RETACRIT

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ERIVEDGE

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic basal cell carcinoma, or B.) Locally advanced basal cell carcinoma that has recurred following surgery or the patient is not a candidate for surgery or radiation
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ERLEADA

Products Affected

- ERLEADA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Nonmetastatic, castration-resistant prostate cancer (nmCRPC), or B.) Metastatic, castration-sensitive prostate cancer (mCSPC). For treatment of nmCRPC and mCSPC, one of the following applies 1.) Used in combination with a gonadotropin-releasing hormone (GnRH) analog, OR 2) Patient has received bilateral orchiectomy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ERLOTINIB

Products Affected

- *erlotinib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally advanced, unresectable, or metastatic pancreatic cancer and erlotinib will be used in combination with gemcitabine, B.) Locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility AND one of the following 1.) Erlotinib will be used as first-line treatment, 2.) Failure with at least one prior chemotherapy regimen, OR 3.) No evidence of disease progression after four cycles of first-line platinum-based chemotherapy and erlotinib will be used as maintenance treatment
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

EVEROLIMUS SUSPENSION

Products Affected

- *everolimus oral tablet soluble 2 mg, 3 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Hypersensitivity to everolimus , or B.) Hypersensitivity to rapamycin derivatives (e.g. sirolimus)
Required Medical Information	Diagnosis of one of the following A.) Tuberous sclerosis complex (TSC)-associated partial-onset seizures, or B.) Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in patients who are not candidates for curative surgical resection
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

EVRYSDI

Products Affected

- EVRYSDI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of spinal muscular atrophy (SMA)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

FASENRA

Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

FEBUXOSTAT

Products Affected

- *febuxostat*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of azathioprine or mercaptopurine
Required Medical Information	Diagnosis of Gout and all of the following 1.) documented inadequate treatment response, adverse event, or contraindication to maximally titrated dose of Allopurinol, and 2.) patients with established cardiovascular disease, prescriber attests that benefit of treatment outweighs the risk of treatment
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

FENTANYL ORAL

Products Affected

- *fentanyl citrate*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Management of acute or postoperative pain (including headache/migraine, dental pain, and use in the emergency room), B.) Use in opioid non-tolerant patients, C.) Known or suspected gastrointestinal obstruction, including paralytic ileus, D.) Acute or severe bronchial asthma and used in an unmonitored setting (absence of resuscitative equipment)
Required Medical Information	Must meet all of the following 1.) Diagnosis of cancer-related breakthrough pain, 2.) Patient is currently receiving/tolerant to around-the-clock opioid therapy for persistent cancer pain, and 3.) Patient and prescriber are enrolled in the TIRF REMS Access Program
Age Restrictions	16 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

FILSPARI

Products Affected

- FILSPARI

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with angiotensin receptor blockers (ARBs), endothelin receptor antagonists (ERAs), or aliskiren
Required Medical Information	Diagnosis of treatment of primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression, generally a urine protein to creatinine ratio (UPCR) of 1.5 g/g or more, to reduce proteinuria
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

FIRMAGON

Products Affected

- FIRMAGON
- FIRMAGON (240 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced prostate cancer
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	B vs D determination required per CMS guidance
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

FOTIVDA

Products Affected

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsed or refractory advanced renal cell cancer (RCC) following 2 or more prior systemic therapies
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

FRUZAQLA

Products Affected

- FRUZAQLA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic colorectal cancer (mCRC) and all of the following: A.) patient has been previously treated with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, B.) an anti-VEGF therapy, and C.) if RAS wild-type and medically appropriate, patient has also been previously treated with anti-EGFR therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

FULPHILA

Products Affected

- FULPHILA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of a non-myeloid malignancy and drug is being used as prophylaxis for chemotherapy-induced neutropenia
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	3 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

FYCOMPA

Products Affected

- FYCOMPA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Partial-onset seizures with or without secondary generalization, or B.) Primary generalized tonic-clonic seizure disorder as adjunctive therapy
Age Restrictions	4 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

GAVRETO

Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

GEFITINIB

Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer (NSCLC) and must meet all of the following 1.) Tumor has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility and 2.) Used as first-line treatment
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

GILOTRIF

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test, or B.) Metastatic squamous NSCLC with progression after platinum-based chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

GLATIRAMER

Products Affected

- *glatiramer acetate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

GLEOSTINE

Products Affected

- GLEOSTINE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet one of the following: A.) Hodgkin's disease in patient who has relapsed during or failed to respond to primary therapy and is being used in combination with other agents OR B.) Intracranial tumor
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

GLP1

Products Affected

- BYDUREON BCISE
- MOUNJARO
- OZEMPIC (0.25 OR 0.5 MG/DOSE)
- OZEMPIC (1 MG/DOSE)
SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML, 4 MG/3ML
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- TRULICITY

PA Criteria	Criteria Details
Exclusion Criteria	Used for weightloss
Required Medical Information	The drug is prescribed for an FDA-approved indication
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

GROWTH HORMONE

Products Affected

- OMNITROPE

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Use for growth promotion in pediatric patients with closed epiphyses, B.) Acute critical illness caused by complications following open-heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure, C.) Active malignancy, D.) Active proliferative or severe nonproliferative diabetic retinopathy, E.) Prader-Willi Syndrome in patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Required Medical Information	Supporting statement of diagnosis from the physician
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or nephrologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HEPATITIS B

Products Affected

- *adefovir dipivoxil*
- BARACLUDE
- *entecavir*
- VEMLIDY

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of chronic hepatitis B and all of the following 1.) Patient has or had evidence of viral replication prior to initiation, 2.) Patient has evidence of persistent elevations in serum aminotransferase (ALT or AST) or histologically active disease, and 3.) Patient is receiving anti-retroviral therapy if the patient has HIV co-infection
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HEPATITIS C

Products Affected

- *ledipasvir-sofosbuvir*
- *sofosbuvir-velpatasvir*
- MAVYRET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must submit documentation of chronic hepatitis C genotype (confirmed by HCV RNA level within the last 6 months). Must submit laboratory results within 12 weeks prior to initiating therapy including: 1) CBC w Platelets, 2) AST/ALT, 3) Total Bilirubin, 4) Serum Albumin, and 5) PT/INR. Genotype and subtype are not required for: (1) initial treatment of patients without cirrhosis if using Sofosbuvir-Velpatasvir or Mavyret OR (2) treatment of patients with compensated cirrhosis if using Mavyret
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist
Coverage Duration	Duration of approval per AASLD Guidelines
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - ANALGESICS

Products Affected

- *butalbital-acetaminophen*
- *butalbital-apap-caffeine*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) The prescribing physician attests to the medical necessity for using this high risk medication.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - ANTI-ARRHYTHMICS

Products Affected

- DIGOXIN ORAL SOLUTION
- *digoxin oral tablet 250 mcg*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) Patient has tried and failed at least one non-HRM alternative, 3.) The prescribing physician attests to the medical necessity for using this high risk medication.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Formulary Non HRM alternatives: propranolol, sotalol, dofetilide, amiodarone, propafenone, mexiletine
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - ANTICHOLINERGIC

Products Affected

- *chlordiazepoxide-clidinium*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) The prescribing physician attests to the medical necessity for using this high risk medication.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - ANTIDEMENTIA

Products Affected

- *ergoloid mesylates*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) Patient has tried and failed at least one non-HRM alternative, 3.) The prescribing physician attests to the medical necessity for using this high risk medication.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Formulary non-HRM alternatives: donepezil, galantamine, memantine, rivastigmine oral
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - ANTIDEPRESSANTS

Products Affected

- *chlordiazepoxide-amitriptyline*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) Patient has tried and failed at least one non-HRM alternative, 3.) The prescribing physician attests to the medical necessity for using this high risk medication.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Formulary non-HRM alternatives: mirtazapine, trazodone, fluoxetine, escitalopram, fluvoxamine, desvenlafaxine, duloxetine, sertraline, venlafaxine, bupropion
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - ANTIHISTAMINES

Products Affected

- *hydroxyzine hcl*
- *hydroxyzine pamoate*
- *promethazine hcl*
- *promethegan*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) Patient has tried and failed at least one non-HRM alternative, 3.) The prescribing physician attests to the medical necessity for using this high risk medication.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Formulary non-HRM alternatives FOR MANAGEMENT OF ALLERGIC CONDITIONS: desloratadine, cetirizine syp, levocetirizine. FOR MANAGEMENT OF ANXIETY/SEDATION: buspirone, trazodone. FOR MANAGEMENT OF NAUSEA/VOMITING: granisetron, ondansetron
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - ANTIPARKINSON AGENTS

Products Affected

- *benztropine mesylate*
- *trihexyphenidyl hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) Patient has tried and failed at least one non-HRM alternative, 3.) The prescribing physician attests to the medical necessity for using this high risk medication.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Formulary non-HRM alternatives: amantadine, carbidopa/levodopa, entacapone, Neupro, pramipexole, ropinirole, selegiline
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - BENZODIAZEPINES

Products Affected

- *alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- *chlordiazepoxide hcl*
- *estazolam*
- *temazepam*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) The prescribing physician attests to the medical necessity for using this high risk medication. For all indications: The prescriber must acknowledge the benefit of therapy with this prescribed medication outweighs the potential risks for the patient. (Note: The American Geriatrics Society identifies the use of this medication as potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) For the management of anxiety disorders: 1) The requested drug is being used concurrently with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI becomes effective for the symptoms of anxiety, OR 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to AT LEAST TWO agents from the following classes: a) selective serotonin reuptake inhibitors (SSRIs), b) serotonin-norepinephrine reuptake inhibitors (SNRIs)
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria
MCS Classicare Formulary 1 - Formulary ID: 25509
Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - CARDIOVASCULAR

Products Affected

- *guanfacine hcl er*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) Patient has tried and failed at least one non-HRM alternative, 3.) The prescribing physician attests to the medical necessity for using this high risk medication.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Formulary Non HRM alternatives: atomoxetine, dexamethylphenidate, methylphenidate
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - MEGESTROL

Products Affected

- *megestrol acetate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) Patient has tried and failed at least one non-HRM alternative, 3.) The prescribing physician attests to the medical necessity for using this high risk medication.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Formulary Non HRM alternatives: dronabinol
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - PCD - BENZODIAZEPINES

Products Affected

- *clonazepam oral tablet 0.5 mg, 1 mg, 2 mg*
- *clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- *clorazepate dipotassium*
- *diazepam intensol*
- *diazepam oral solution*
- *diazepam oral tablet*
- *lorazepam*
- *lorazepam intensol*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of seizure disorder or must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) The prescribing physician attests to the medical necessity for using this high risk medication. For all indications: The prescriber must acknowledge the benefit of therapy with this prescribed medication outweighs the potential risks for the patient. (Note: The American Geriatrics Society identifies the use of this medication as potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) For the management of anxiety disorders: 1) The requested drug is being used concurrently with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI becomes effective for the symptoms of anxiety, OR 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to AT LEAST TWO agents from the following classes: a) selective serotonin reuptake inhibitors (SSRIs), b) serotonin-norepinephrine reuptake inhibitors (SNRIs).
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria
MCS Classicare Formulary 1 - Formulary ID: 25509
Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - SEDATIVE HYPNOTICS

Products Affected

- *zaleplon*
- *zolpidem tartrate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to doxepin (3 mg or 6 mg)3.)The prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for the patient. (Note: The American Geriatrics Society identifies the use of this medication as potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.)
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Formulary non-HRM alternatives: Belsonra, doxepin 3mg and 6mg tablets, trazodone
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HRM - SKELETAL MUSCLE RELAXANTS

Products Affected

- *cyclobenzaprine hcl*
- *orphenadrine citrate er*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) The drug is being prescribed for an FDA-approved indication, 2.) Patient has tried and failed at least one non-HRM alternative, 3.) The prescribing physician attests to the medical necessity for using this high risk medication
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior Auth required for age 65 or older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	Formulary Non HRM alternatives: baclofen
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

HYFTOR

Products Affected

- HYFTOR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Facial angiofibroma associated with tuberous sclerosis
Age Restrictions	6 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

IBRANCE

Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer used in combination with fulvestrant and disease has progressed following endocrine therapy, or B.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and used in combination with an aromatase inhibitor in a male or female patient as initial endocrine-based therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ICATIBANT

Products Affected

- *icatibant acetate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hereditary angioedema AND medication will be used for the treatment of acute attacks
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an allergist, hematologist, or immunologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ICLUSIG

Products Affected

- ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

IDHIFA

Products Affected

- IDHIFA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation as detected by an FDA approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

IMATINIB

Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

IMBRUVICA

Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL), B.) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion, C.) Waldenstrom's macroglobulinemia (WM), or D.) Chronic graft vs host disease (cGVHD) after failure of at least one first-line corticosteroid therapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

IMPAVIDO

Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
Exclusion Criteria	Sjogren-Larsson-Syndrome
Required Medical Information	Diagnosis of one of the following: A.) Visceral leishmaniasis caused by <i>Leishmania donovani</i> , B.) Cutaneous leishmaniasis caused by <i>Leishmania braziliensis</i> , <i>Leishmania guyanensis</i> , and <i>Leishmania panamensis</i> , or C.) Mucosal leishmaniasis caused by <i>Leishmania braziliensis</i>
Age Restrictions	12 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

INCRELEX

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Active or suspected malignancy, B.) Use for growth promotion in patients with closed epiphyses, or C.) Intravenous administration
Required Medical Information	Diagnosis of one of the following A.) Severe primary insulin-like growth factor-1 (IGF-1) deficiency and utilized for pediatric treatment of growth failure, or B.) Growth hormone (GH) gene deletion and patient has developed neutralizing antibodies to GH and utilized for pediatric treatment of growth failure
Age Restrictions	2 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

INJECTABLE TESTOSTERONE

Products Affected

- *testosterone cypionate*
- *testosterone enanthate*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Carcinoma of the breast (males only), or B.) Known or suspected carcinoma of the prostate
Required Medical Information	Diagnosis of one of the following A.) Hypogonadotropic hypogonadism, B.) Inoperable metastatic breast cancer in women who are postmenopausal (testosterone enanthate), C.) Primary hypogonadism, or D.) Delayed puberty (testosterone enanthate). Diagnosis of hypogonadism must be confirmed by a low-for-age serum testosterone (total or free) level defined by the normal laboratory reference value
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

INLYTA

Products Affected

- INLYTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma and patient failed one or more systemic therapies for renal cell carcinoma (e.g., sunitinib-, bevacizumab-, temsirolimus-, or cytokine-containing regimens), or B.) Advanced renal cell carcinoma and used as first-line therapy in combination with avelumab or pembrolizumab
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

INQOVI

Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

INREBIC

Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

INVEGA HAFYERA

Products Affected

- INVEGA HAFYERA
INTRAMUSCULAR SUSPENSION
- PREFILLED SYRINGE 1092 MG/3.5ML,
1560 MG/5ML

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following A.) Diagnosis of schizophrenia, and B.) Adequate treatment has been established with Invega Sustenna for at least 4 months or Invega Trinza for at least one three-month injection cycle
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an psychiatrist
Coverage Duration	Plan Year
Other Criteria	For continuation of therapy member must be re-evaluated by the psychiatrist to assess clinical response. Treatment should be discontinued if failure to therapy or an adverse event is documented or the member does not demonstrate adherence to treatment
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

INVEGA SUSTENNA

Products Affected

- INVEGA SUSTENNA 156 MG/ML, 234 MG/1.5ML, 39
INTRAMUSCULAR SUSPENSION MG/0.25ML, 78 MG/0.5ML
PREFILLED SYRINGE 117 MG/0.75ML,

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet one of the following A.) Diagnosis of schizophrenia and all of the following 1.) trial and failure, contraindication, or intolerance to two oral second-generation antipsychotics, 2.) Trial and failure to respond to haloperidol decanoate and fluphenazine decanoate, 3.) Member has established response and tolerability to oral paliperidone, and 4.) Patient presents history of noncompliance with oral medications and documentation is provided on the efforts to improve medication adherence, or B.) Diagnosis of schizoaffective disorder and both of the following 1.) Member has established response and tolerability to oral paliperidone and 2.) Patient presents history of noncompliance with oral medications and documentation is provided on the efforts to improve medication adherence
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an psychiatrist
Coverage Duration	Plan Year
Other Criteria	For continuation of therapy member must be re-evaluated by the psychiatrist to assess clinical response. Treatment should be discontinued if failure to therapy or an adverse event is documented or the member does not demonstrate adherence to treatment
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

Prior Authorization Criteria
MCS Classicare Formulary 1 - Formulary ID: 25509
Effective date: 01/01/2025 Last Updated: 09/26/2024

INVEGA TRINZA

Products Affected

- INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following A.) Diagnosis of schizophrenia, and B.) Adequate treatment has been established with Invega Sustenna for at least 4 months
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an psychiatrist
Coverage Duration	Plan Year
Other Criteria	For continuation of therapy member must be re-evaluated by the psychiatrist to assess clinical response. Treatment should be discontinued if failure to therapy or an adverse event is documented or the member does not demonstrate adherence to treatment
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ITRACONAZOLE

Products Affected

- *itraconazole*

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

IVABRADINE

Products Affected

- *ivabradine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

IVERMECTIN

Products Affected

- *ivermectin*

PA Criteria	Criteria Details
Exclusion Criteria	Prevention or treatment of COVID-19
Required Medical Information	Diagnosis of one of the following: A.) Strongyloidiasis of the intestinal tract or B.) Onchocerciasis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	1 month
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

IWILFIN

Products Affected

- IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of high-risk neuroblastoma to be used to reduce the risk of relapse in adult and pediatric patients who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

JAKAFI

Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis, B.) Polycythemia vera AND patient has had an inadequate response to or is intolerant of hydroxyurea, C.) Acute graft versus host disease AND disease is refractory to steroid therapy, or D.) Chronic graft-versus-host disease (cGVHD) after failure of corticosteroid therapy (alone or in combination with a calcineurin inhibitor) and up to one additional line of systemic therapy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

JAYPIRCA

Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) relapsed or refractory mantle cell lymphoma (MCL) and is being used after at least two lines of systemic therapy, including a BTK inhibitor or B.) chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

JOENJA

Products Affected

- JOENJA

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

KALYDECO

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (CF) and the patient has 1 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

KERENDIA

Products Affected

- KERENDIA

PA Criteria	Criteria Details
Exclusion Criteria	none
Required Medical Information	Diagnosis of Chronic kidney disease associated with Type 2 diabetes mellitus AND patient is currently receiving the following standard of care A.) A maximally tolerated dose of ACE inhibitor, ARB, or a combination medication containing an ACE or ARB AND B.) Antidiabetic agent (e.g., metformin or an agent containing metformin, SGLT2 inhibitor, GLP-1 RA)
Age Restrictions	none
Prescriber Restrictions	none
Coverage Duration	12 months
Other Criteria	none
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

KISQALI

Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

KISQALI FEMARA

Products Affected

- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and one of the following A.) The patient is pre-or perimenopausal woman or male and the requested drug will be used as initial endocrine-based therapy, B.) The patient is postmenopausal, the requested drug will be used as initial endocrine-based therapy, and the patient has experienced disease progression, an intolerable adverse event, or contraindication to Ibrance (palbociclib) or Verzenio (abemaciclib)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

KORLYM

Products Affected

- KORLYM

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Coadministration with simvastatin, lovastatin, or CYP3A substrates with narrow therapeutic ranges, B.) Concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses, C.) History of unexplained vaginal bleeding, D.) Endometrial hyperplasia with atypia or endometrial carcinoma
Required Medical Information	Diagnosis of endogenous Cushing syndrome in patients with type 2 diabetes mellitus or glucose intolerance and must meet all of the following 1.) Used to control hyperglycemia secondary to hypercortisolism, AND 2.) Patient has failed or is not a candidate for surgery
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

KOSELUGO

Products Affected

- KOSELUGO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of neurofibromatosis type 1 (NF1) in a patient who has symptomatic, inoperable plexiform neurofibromas (PN)
Age Restrictions	2 years of age to 17 years of age
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

KRAZATI

Products Affected

- KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LAPATINIB

Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced or metastatic breast cancer with tumors that overexpress human epidermal growth factor receptor 2 (HER2) AND meets one of the following A.) Used in combination with capecitabine in a patient who has received prior therapy including an anthracycline, a taxane, and trastuzumab, OR B.) Used in combination with letrozole in a postmenopausal female for whom hormonal therapy is indicated
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LENALIDOMIDE

Products Affected

- *lenalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Multiple myeloma and medication will be used in combination with dexamethasone, B.) Autologous hematopoietic stem-cell transplantation (HSCT) in multiple myeloma patients, C.) Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality or without additional cytogenetic abnormalities, D.) Mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib, E.) Follicular lymphoma and used in combination with rituximab, or F.) Marginal zone lymphoma and used in combination with rituximab
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LENVIMA

Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, B.) Advanced renal cell carcinoma, in combination with everolimus, following one prior anti-angiogenic therapy, C.) Unresectable hepatocellular carcinoma, first-line therapy, D.) Advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, in combination with pembrolizumab, when disease has progressed following prior systemic therapy and patient is not a candidate for curative surgery or radiation, or E.) Advanced renal cell carcinoma, in combination with pembrolizumab and used as first-line therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LEUKINE

Products Affected

- LEUKINE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Patient has undergone allogeneic or autologous bone marrow transplant (BMT) and engraftment is delayed or failed, B.) Patient is undergoing autologous peripheral-blood progenitor cell transplant to mobilize progenitor cells for collection by leukapheresis, C.) Medication will be used for myeloid reconstitution after an autologous or allogeneic BMT, D.) Patient has acute myeloid leukemia and administration will be after completion of induction chemotherapy, E.) Hematopoietic subsyndrome of acute radiation syndrome (H-ARS) or F.) Autologous peripheral blood stem cell transplant, Following myeloablative chemotherapy.
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LEUPROLIDE

Products Affected

- ELIGARD SUBCUTANEOUS KIT 22.5 MG, 30 MG, 45 MG, 7.5 MG
- *leuprolide acetate*
- LEUPROLIDE ACETATE (3 MONTH)
- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)
- LUPRON DEPOT-PED (1-MONTH)
- LUPRON DEPOT-PED (3-MONTH)
- LUPRON DEPOT-PED (6-MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet one of the following: 1.) Eligard only: Advanced or metastatic prostate cancer, or 2.) For Lupron depot and leuprolide products only: A.) Advanced or metastatic prostate cancer and patient has failed or is intolerant to Eligard or Trelstar (7.5 mg 1-month, 22.5 mg 3-month, 30 mg 4-month, and 45 mg 6-month depots only), B.) Endometriosis (3.75 mg 1-month and 11.25 mg 3-month depots only), C.) Anemia due to uterine leiomyomata (Fibroids) (3.75 mg 1-month and 11.25 mg 3-month depots only) and patient is preoperative, or D.) Central precocious puberty (idiopathic or neurogenic) in children
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	B vs D determination required per CMS guidance
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

L-GLUTAMINE

Products Affected

- *l-glutamine*

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LIDOCAINE EXT

Products Affected

- *lidocaine external ointment*
- *lidocaine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	Amide hypersensitivity
Required Medical Information	The requested drug will be used for or topical anesthesia of skin or mucous membranes
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LINEZOLID

Products Affected

- *linezolid intravenous*
- *linezolid oral tablet*
- *linezolid oral suspension reconstituted*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant use of an MAOI, or B.) Use within 14 days of discontinuing an MAOI
Required Medical Information	Diagnosis of one of the following A.) Community acquired pneumonia, B.) Hospital-acquired pneumonia, C.) Vancomycin-resistant Enterococcus faecium infection, D.) Complicated skin and skin structure infections, or E.) Uncomplicated skin and skin structure infections
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	1 month
Other Criteria	B vs D determination required per CMS guidance
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LIVTENCITY

Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet
Age Restrictions	12 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LONSURF

Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic colorectal cancer, previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based regimens, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy, or B.) Metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan and if appropriate, HER2/neu-targeted therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LORBRENA

Products Affected

- LORBRENA ORAL TABLET 100 MG,
25 MG

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with strong CYP3A4 inducers
Required Medical Information	Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LUMAKRAS

Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 320 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, and patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

LYNPARZA

Products Affected

- LYNPARZA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Diagnosis of one of the following A.) HER2-negative, deleterious or suspected deleterious germline BRCA mutated high-risk early or metastatic breast cancer AND patient has been previously treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting, B.) Recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer AND used for maintenance treatment in patients who are in complete or partial response to platinum-based chemotherapy (e.g. cisplatin, carboplatin), C.) Deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with complete or partial response to first-line platinum-based chemotherapy, D.) Deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma and disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen, E.) Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA-mutation and/or genomic instability AND are using in combination with bevacizumab for maintenance treatment, F.) Deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutated metastatic castration-resistant prostate cancer in patients who have progressed following prior treatment with enzalutamide or abiraterone, or G.) Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer in combination with abiraterone and prednisone or prednisolone</p>
Age Restrictions	18 years of age and older

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria
MCS Classicare Formulary 1 - Formulary ID: 25509
Effective date: 01/01/2025 Last Updated: 09/26/2024

LYTGOBI

Products Affected

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements and previously treated
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

MATULANE

Products Affected

- MATULANE

PA Criteria	Criteria Details
Exclusion Criteria	Inadequate marrow reserve
Required Medical Information	Diagnosis of Hodgkin's Disease, Stages III and IV and used in combination with other anticancer drugs
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

MAYZENT

Products Affected

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) CYP2C9*3/*3 genotype, B.) In the last 6 months experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, Class III-IV heart failure, or C.) Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

MEKINIST

Products Affected

- MEKINIST

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and used in combination with dabrafenib and no locoregional treatment options, B.) Malignant melanoma with lymph node involvement and following complete resection with BRAF V600E or V600K mutations and used in combination with dabrafenib, C.) Unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutations and used in combination with dabrafenib or as monotherapy, D.) Metastatic non-small cell lung cancer, with BRAF V600E mutation, in combination with dabrafenib, E.) Unresectable or metastatic solid tumors with BRAF V600E mutation, in combination with dabrafenib, and have progressed following prior treatment and have no satisfactory alternative treatment options, F.) Low-grade glioma with a BRAF V600E mutation and require systemic therapy, in combination with dabrafenib
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

MEKTOVI

Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Unresectable or metastatic malignant melanoma with documented BRAF V600E or V600K mutation as detected by an FDA approved test AND used in combination with encorafenib or B.) Metastatic non-small cell lung cancer with a BRAF V600E mutation as detected by an FDA-approved test AND used in combination with encorafenib
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

MIFEPRISTONE

Products Affected

- *mifepristone*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Coadministration with simvastatin, lovastatin, or CYP3A substrates with narrow therapeutic ranges, B.) Concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses, C.) History of unexplained vaginal bleeding, D.) Endometrial hyperplasia with atypia or endometrial carcinoma
Required Medical Information	Diagnosis of endogenous Cushing syndrome in patients with type 2 diabetes mellitus or glucose intolerance and must meet all of the following 1.) Used to control hyperglycemia secondary to hypercortisolism, and 2.) Patient has failed or is not a candidate for surgery
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

MIGLUSTAT

Products Affected

- *miglustat*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of mild to moderate type 1 Gaucher disease and patient is not a candidate for enzyme replacement therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

NAYZILAM

Products Affected

- NAYZILAM

PA Criteria	Criteria Details
Exclusion Criteria	Acute narrow angle glaucoma
Required Medical Information	Diagnosis of epilepsy and documentation of acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures), that are distinct from a patient's usual seizure pattern
Age Restrictions	12 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	This criteria applies to new starts only
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

NERLYNX

Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Early stage HER2-positive breast cancer and used following adjuvant trastuzumab therapy, or B.) Advanced or metastatic HER2-positive breast cancer, used in combination with capecitabine, AND patient has received 2 or more prior anti-HER2-based regimens in the metastatic setting
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

NINLARO

Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of multiple myeloma, used in combination with lenalidomide and dexamethasone, AND patient has history of at least 1 prior therapy . Examples include bortezomib, cyclophosphamide, Kyprolis (carfilzomib intravenous infusion), lenalidomide, Darzalex (daratumumab intravenous infusion).
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

NUBEQA

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Non-metastatic, castration-resistant prostate cancer (nmCRPC) or B.) Metastatic hormone-sensitive prostate cancer in combination with docetaxel. For treatment of nmCRPC, one of the following applies 1.) Used in combination with a gonadotropin-releasing hormone (GnRH) analog or 2) Patient has received bilateral orchiectomy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

NUEDEXTA

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) History of prolonged QT interval, congenital long QT syndrome or Torsades de pointes, B.) Heart failure, C.) Complete AV block without an implanted pacemaker or high risk of complete AV block, D.) Concomitant use with quinidine, quinine, mefloquine, or drugs that prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine, pimozide), E.) Concomitant use with MAOIs or within 14 days of MAOI therapy, F.) History of quinine-, mefloquine-, or quinidine-induced thrombocytopenia, bone marrow depression, or lupus-like syndrome
Required Medical Information	Diagnosis of pseudobulbar affect
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

NUPLAZID

Products Affected

- NUPLAZID

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Parkinson's disease and both of the following apply A.) Used for treatment of hallucinations and/or delusions associated with Parkinson's disease psychosis, and B.) Diagnosis of Parkinson's disease was made prior to the onset of psychotic symptoms
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

OCTREOTIDE

Products Affected

- *octreotide acetate*

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ODOMZO

Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of locally advanced basal cell carcinoma of the skin and one of the following A.) Cancer has recurred following surgery or radiation therapy, B.) Patient is not a candidate for surgery or radiation therapy.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

OFEV

Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Idiopathic pulmonary fibrosis (IPF), B.) Systemic sclerosis-associated interstitial lung disease (ILD), or C.) Chronic fibrosing interstitial lung disease with a progressive phenotype
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

OGSIVEO

Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of progressing desmoid tumors who require systemic treatment
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

OJEMDA

Products Affected

- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

OJJAARA

Products Affected

- OJJAARA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ONUREG

Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of acute myeloid leukemia (AML) used in maintenance treatment for adult patients who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

OPSUMIT

Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of pulmonary arterial hypertension (WHO Group I), confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e. g., patient is frail, elderly, etc.)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	Initial: 6 months, Renewal: Plan Year
Other Criteria	Continuation of therapy: patient is tolerating and responding to medication and has improved exercise capacity or a delay in clinical worsening.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

OPSYNVI

Products Affected

- OPSYNVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of pulmonary arterial hypertension (WHO Group I), confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e. g., patient is frail, elderly, etc.)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	Initial: 6 months, Renewal: Plan Year
Other Criteria	Continuation of therapy: patient is tolerating and responding to medication and has improved exercise capacity or a delay in clinical worsening.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ORENCIA

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MG/ML, 50 MG/0.4ML, 87.5 MG/0.7ML

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis, B.) Moderate to severe polyarticular juvenile idiopathic arthritis, C.) Psoriatic arthritis, or D.) Prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in patients undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor.
Age Restrictions	For RA: 18 years of age or older. All other indications 2 years of age or older.
Prescriber Restrictions	For RA and PJIA: Rheumatologist, For PsA: Dermatologist or Rheumatologist, For aGVHD: Hematologist or Transplant Specialist.
Coverage Duration	Plan Year
Other Criteria	Only for biologic therapy-naive patients: Physician's certification stating tuberculosis (TB) negative status or negative result of a TB detection test with a reading date less than 12 months before the start of therapy or chest x ray.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ORGOVYX

Products Affected

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced prostate cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ORKAMBI

Products Affected

- ORKAMBI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (CF) with documented homozygous F508del mutation confirmed by FDA-approved CF mutation test
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ORSERDU

Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced or metastatic, ER-positive, HER2-negative, ESR1-mutated, breast cancer in postmenopausal women or adult man after at least 1 line of endocrine therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

OTEZLA

Products Affected

- OTEZLA ORAL TABLET
- OTEZLA ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PANRETIN

Products Affected

- PANRETIN

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PAZOPANIB

Products Affected

- *pazopanib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma (RCC), or B.) Advanced soft tissue sarcoma (STS), has received prior chemotherapy and does not have adipocytic soft tissue sarcoma (STS) or gastrointestinal stromal tumors (GIST)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PEGYLATED INTERFERON

Products Affected

- PEGASYS

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PEMAZYRE

Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with confirmed fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test or B.) Relapsed or refractory myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, gastroenterologist, or hepatologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PENICILLAMINE

Products Affected

- *penicillamine*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Breastfeeding, B.) Hypersensitivity to penicillamine products, C.) Penicillamine-related aplastic anemia/agranulocytosis, or D.) Rheumatoid arthritis patients with history or evidence of renal insufficiency
Required Medical Information	Diagnosis of one of the following A.) Cystinuria, B.) Severe, active rheumatoid arthritis, or C.) Wilson's disease
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PIQRAY

Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PIRFENIDONE

Products Affected

- *pirfenidone*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of idiopathic pulmonary fibrosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

POMALYST

Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) AIDS-related Kaposi sarcoma and patient has failure on highly active antiretroviral therapy (HAART), B.) Kaposi sarcoma in HIV-negative adults, or C.) Multiple myeloma and in combination with dexamethasone in adults who have received at least 2 prior therapies (including lenalidomide and a proteasome inhibitor) and have demonstrated disease progression on or within 60 days of completion of the last therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

POSACONAZOLE

Products Affected

- *posaconazole*

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PREVYMIS

Products Affected

- PREVYMIS

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant use with pimozone or ergot alkaloids (ergotamine, dihydroergotamine), B.) Concomitant use with pitavastatin or simvastatin when coadministered with cyclosporine
Required Medical Information	Diagnosis of one of the following A.) Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant, or B.) Prophylaxis of CMV disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-])
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PROLIA

Products Affected

- PROLIA

PA Criteria	Criteria Details
Exclusion Criteria	Hypocalcemia (calcium less than 8.0 mg/dL)
Required Medical Information	Must meet all of the following A.) Diagnosis of one of the following 1.) Treatment of osteoporosis in postmenopausal females at high risk of fracture, 2.) Treatment of osteoporosis in males at high risk of fracture 3.) Treatment of bone loss in males receiving androgen-deprivation therapy for nonmetastatic prostate cancer, 4.) Treatment of bone loss in females receiving aromatase inhibitor therapy for breast cancer, or 5.) Treatment of glucocorticoid-induced osteoporosis in patients at high risk of fracture who are initiating or continuing systemic glucocorticoids at a daily dose greater than or equal to 7.5 mg of prednisone for an anticipated duration of at least 6 months B.) Bone density scan (DEXA) documenting a T-score less than -1.0 at lumbar spine, total hip, femoral neck, or 33% radius and member has high risk factors (high risk defined as osteoporotic fracture history, multiple risk factors for fracture, or failure of or intolerance to other available osteoporosis therapy) or T-score less than or equal to -2.5 in the lumbar spine, total hip, femoral neck, or 33% radius
Age Restrictions	none
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

Prior Authorization Criteria
MCS Classicare Formulary 1 - Formulary ID: 25509
Effective date: 01/01/2025 Last Updated: 09/26/2024

PROMACTA

Products Affected

- PROMACTA ORAL PACKET 12.5 MG, 25 MG
- PROMACTA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic idiopathic thrombocytopenic purpura (ITP), B.) Chronic hepatitis C infection associated thrombocytopenia, or C.) Severe aplastic anemia with insufficient response to immunosuppressive therapy or in combination with standard immunosuppressive therapy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PULMOZYME

Products Affected

- PULMOZYME

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (CF)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	Plan Year
Other Criteria	B vs D determination required per CMS guidance
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PURIXAN

Products Affected

- PURIXAN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) Diagnosis of acute lymphocytic leukemia, 2.) Using in combination with methotrexate, 3.) Patient has tried/failed or has contraindication/intolerance to mercaptopurine tablets
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PYRIMETHAMINE

Products Affected

- *pyrimethamine*

PA Criteria	Criteria Details
Exclusion Criteria	Documented megaloblastic anemia due to folate deficiency
Required Medical Information	Diagnosis of Toxoplasmosis and treatment in combination with a sulfonamide
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist
Coverage Duration	10 weeks
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

QINLOCK

Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced gastrointestinal stromal tumor (GIST) and patient has received prior treatment with 3 or more kinase inhibitors, including imatinib
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

QUININE SULFATE

Products Affected

- *quinine sulfate*

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RAVICTI

Products Affected

- RAVICTI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of urea cycle disorders
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

REGRANEX

Products Affected

- REGRANEX

PA Criteria	Criteria Details
Exclusion Criteria	Known neoplasm at the site of application
Required Medical Information	Diagnosis of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply
Age Restrictions	16 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

REPATHA

Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH), B.) homozygous familial hypercholesterolemia, C.) established cardiovascular disease and myocardial infarction prophylaxis, stroke prophylaxis, or coronary revascularization prophylaxis is required, or D.) clinical atherosclerotic cardiovascular disease (CVD) as defined as one of the following 1.) acute coronary syndrome, 2.) history of myocardial infarction, 3.) stable/unstable angina, 4.) coronary or other arterial revascularization, 5.) stroke, 6.) transient ischemic stroke (TIA), or 7.) peripheral arterial disease presumed to be atherosclerotic region
Age Restrictions	10 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RETEVMO

Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced or metastatic RET-mutant medullary thyroid cancer (MTC) in patients who require systemic therapy, B.) Metastatic RET fusion-positive non-small cell lung cancer (NSCLC), C.) Advanced or metastatic RET fusion-positive thyroid cancer in patients who require systemic therapy and are refractory to radioactive iodine, if appropriate, or D.) Locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

REVLIMID

Products Affected

- REVLIMID

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Multiple myeloma and medication will be used in combination with dexamethasone, B.) Autologous hematopoietic stem-cell transplantation (HSCT) in multiple myeloma patients, C.) Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality or without additional cytogenetic abnormalities, D.) Mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib, E.) Follicular lymphoma and used in combination with rituximab, or F.) Marginal zone lymphoma and used in combination with rituximab
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

REZLIDHIA

Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

REZUROCK

Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of chronic graft-vs-host disease and patient has failed at least 2 prior lines of systemic therapy (e.g., prednisone, methotrexate, cyclosporine, tacrolimus, mycophenolate, Imbruvica (ibrutinib), Jakafi (ruxolitinib), etc.)
Age Restrictions	12 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RILUZOLE

Products Affected

- *riluzole*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of amyotrophic lateral sclerosis (ALS)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RINVOQ

Products Affected

- RINVOQ

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RINVOQ LQ

Products Affected

- RINVOQ LQ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Active psoriatic arthritis with inadequate response or intolerance to 1 or more TNF blockers, or B.) Active polyarticular juvenile idiopathic arthritis with inadequate response or intolerance to 1 or more TNF blockers
Age Restrictions	2 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a rheumatologist
Coverage Duration	Plan year
Other Criteria	Screening for latent tuberculosis infection is required prior to initiation of treatment
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RIVFLOZA

Products Affected

- RIVFLOZA SUBCUTANEOUS SOLUTION
- RIVFLOZA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 128 MG/0.8ML, 160 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Primary hyperoxaluria type 1 and the patient has relatively preserved kidney function (eGFR is greater than or equal to 30mL/min/1.73m ²)
Age Restrictions	9 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a NEPHROLOGIST
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ROZLYTREK

Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PACKET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) ROS1-positive metastatic non-small cell lung cancer (NSCLC), or B.) Solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	Verify the pregnancy status of females of reproductive potential prior to initiating ROZLYTREK
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RUBRACA

Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, used as maintenance treatment, and patient is in complete or partial response to platinum-based chemotherapy, or B.) Deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer and patient has been treated with androgen receptor-directed therapy and a taxane-based chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RUFINAMIDE

Products Affected

- *rufinamide oral suspension*

PA Criteria	Criteria Details
Exclusion Criteria	Familial Short QT Syndrome
Required Medical Information	Diagnosis of seizures associated with Lennox-Gastaut syndrome and used as adjunctive treatment
Age Restrictions	1 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RYDAPT

Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SAPROPTERIN

Products Affected

- *sapropterin dihydrochloride*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hyperphenylalaninemia (HPA) caused by tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Initial: 2 months, Renewal: Plan year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SCSEMBLIX

Products Affected

- SCSEMBLIX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), or B.) Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SIGNIFOR

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Cushing disease and patient has had inadequate response to or is not a candidate for surgery. For renewal: Documentation of a clinically meaningful reduction in 24-hour urinary free cortisol (UFC) levels or improvement in signs or symptoms of the disease
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SILDENAFIL

Products Affected

- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Nitrate therapy, including intermittent use, B.) Concomitant use with riociguat or other guanylate cyclase stimulators, C.) Concomitant use with HIV protease inhibitors or elvitegravir/cobicistat/tenofovir/emtricitabine
Required Medical Information	Diagnosis of pulmonary arterial hypertension (WHO Group I), confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	12 months
Other Criteria	Continuation of therapy: patient is tolerating and responding to medication and has improved exercise capacity or a delay in clinical worsening.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SIRTURO

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Must meet all of the following 1.) Diagnosis of pulmonary multidrug resistant tuberculosis (MDR-TB) and 2.) Used in combination with at least 3 other antibiotics for the treatment of pulmonary multi-drug resistant tuberculosis
Age Restrictions	5 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist
Coverage Duration	24 weeks
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SKYRIZI

Products Affected

- SKYRIZI (150 MG DOSE)
- SKYRIZI PEN
- SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180 MG/1.2ML, 360 MG/2.4ML
- SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SODIUM OXYBATE

Products Affected

- *sodium oxybate*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant treatment with sedative hypnotic agents, B.) Succinic semialdehyde dehydrogenase deficiency
Required Medical Information	Diagnosis of one of the following A.) Narcolepsy with excessive daytime drowsiness and has trial of/or contraindication to a central nervous system (CNS) stimulant drug (e.g., amphetamine, dextroamphetamine, methylphenidate) or a CNS wakefulness promoting drug (e.g., armodafinil, modafinil), or B.) Cataplexy and narcolepsy
Age Restrictions	7 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SOLTAMOX

Products Affected

- SOLTAMOX

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant coumarin-type anticoagulant therapy, B.) history of thromboembolic disease such as DVT or PE
Required Medical Information	Diagnosis of breast cancer and documentation of inability to swallow tablet formulation
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SOMAVERT

Products Affected

- SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10 MG, 15 MG, 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of acromegaly confirmed by high pretreatment insulin-like growth factor-1 (IGF-1) level for age and/or gender based on the laboratory reference range and patient has had an inadequate response to or is ineligible for surgery or radiation therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SORAFENIB

Products Affected

- *sorafenib tosylate*

PA Criteria	Criteria Details
Exclusion Criteria	Squamous cell lung cancer being treated with carboplatin and paclitaxel
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma, B.) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment, or C.) Unresectable hepatocellular carcinoma
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SPRYCEL

Products Affected

- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, B.) Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, C.) Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy, or D.) Newly diagnosed Ph+ ALL in combination with chemotherapy
Age Restrictions	1 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

STELARA

Products Affected

- STELARA SUBCUTANEOUS SOLUTION
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severely active Crohn's disease, B.) Moderate to severe plaque psoriasis, C.) Active psoriatic arthritis, or D.) Moderate to severe active ulcerative colitis. For moderate to severe plaque psoriasis: 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) the patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected)
Age Restrictions	For PSO or PsA: 6 years of age or older, For all other indications: 18 years of age or older
Prescriber Restrictions	For PsO: Dermatologist, For PsA: Dermatologist or Rheumatologist, For CD and UC: Gastroenterologist.
Coverage Duration	Plan Year
Other Criteria	Only for biologic therapy-naive patients: Physician's certification stating tuberculosis (TB) negative status or negative result of a TB detection test with a reading date less than 12 months before the start of therapy or chest x ray.

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria
MCS Classicare Formulary 1 - Formulary ID: 25509
Effective date: 01/01/2025 Last Updated: 09/26/2024

STIVARGA

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic colorectal cancer in patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan containing chemotherapy, anti-VEGF therapy, and if RAS wild type, anti-EGFR therapy, B.) Liver carcinoma in patients previously treated with sorafenib, or C.) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with imatinib and sunitinib
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SUNITINIB

Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Gastrointestinal stromal tumor after disease progression on or intolerance to imatinib, B.) Pancreatic neuroendocrine tumors in a patient with unresectable locally advanced or metastatic disease, C.) Advanced renal cell carcinoma, or D.) Renal cell carcinoma and used as adjuvant therapy following nephrectomy in patients who are at high risk for recurrence
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SYMLIN

Products Affected

- SYMLINPEN 120
- SYMLINPEN 60

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Confirmed diagnosis of gastroparesis, B.) Hypoglycemia unawareness
Required Medical Information	Diagnosis of type 1 or type 2 diabetes mellitus and patient uses mealtime insulin therapy and has failed to achieve desired glucose control
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

SYNAREL

Products Affected

- SYNAREL

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Breastfeeding, or B.) undiagnosed abnormal vaginal bleeding
Required Medical Information	Diagnosis of one of the following A.) Central precocious puberty, or B.) Endometriosis
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TABRECTA

Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TADALAFIL

Products Affected

- *tadalafil*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) concurrent use of nitrates, including intermittent use, or B.) diagnosis of erectile dysfunction without signs and symptoms of BPH
Required Medical Information	Diagnosis of benign prostatic hyperplasia (BPH) and patient has experienced intolerance to or treatment failure to ONE alpha-blocker (e.g., doxazosin, prazosin, tamsulosin) AND to ONE 5-alpha reductase inhibitor (e.g., dutasteride, finasteride).
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a urologist
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TAFINLAR

Products Affected

- TAFINLAR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Locally advanced or metastatic anaplastic thyroid carcinoma with BRAF V600E mutation, in combination with trametinib and no satisfactory locoregional treatment options, B.) Metastatic non-small cell lung cancer with BRAF V600E mutation, in combination with trametinib OR in patients previously treated as monotherapy, C.) Unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutation, D.) Unresectable or metastatic solid tumors with BRAF V600E mutation, in combination with trametinib, and have progressed following prior treatment and have no satisfactory alternative treatment options, or E.) Low-grade glioma with a BRAF V600E mutation and require systemic therapy, in combination with trametinib
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TAGRISO

Products Affected

- TAGRISO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R mutation and used as first line therapy, B.) Metastatic non-small cell lung cancer with T790M EGFR mutation (as confirmed by an FDA-approved test) AND whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy, C.) Non-small cell lung cancer (NSCLC) with tumor epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as confirmed by an FDA-approved test) AND patient requires adjuvant therapy after tumor resection, or D.) First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, in combination with pemetrexed and platinum-based chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TALZENNA

Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or B.) Homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer in combination with enzalutamide
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TASIGNA

Products Affected

- TASIGNA

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Long QT syndrome, B.) Uncorrected hypokalemia, C.) Uncorrected hypomagnesemia
Required Medical Information	Diagnosis of one of the following A.) Newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML), B.) Chronic phase or accelerated phase Philadelphia chromosome-positive CML in a patient with resistance or intolerance to prior therapy that included imatinib, or C.) Chronic phase Philadelphia chromosome-positive CML in a patient with resistance or intolerance to prior tyrosine-kinase inhibitor therapy
Age Restrictions	1 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TAVNEOS

Products Affected

- TAVNEOS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) and both of the following apply 1.) Used as adjunctive treatment, and 2.) Used in combination with standard therapy including glucocorticoids
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TAZAROTENE

Products Affected

- *tazarotene external cream*
- *tazarotene external gel*
- TAZORAC

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Acne vulgaris and patient has trial with at least one generic topical acne product, or B.) Stable moderate to severe plaque psoriasis with 20% or less body surface area involvement and patient has trial with at least one other topical psoriasis product (e.g., medium to high potency corticosteroid and/or vitamin D analogs)
Age Restrictions	12 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TAZVERIK

Products Affected

- TAZVERIK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic or locally advanced epithelioid sarcoma in patients not eligible for complete resection, B.) Relapsed or refractory follicular lymphoma in patients whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, or C.) Relapsed or refractory follicular lymphoma in patients who have no satisfactory alternative treatment options
Age Restrictions	16 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TEPMETKO

Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping alterations
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TERIPARATIDE

Products Affected

- TERIPARATIDE (RECOMBINANT)

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TETRABENAZINE

Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Actively suicidal, B.) Untreated or inadequately treated depression, C.) Impaired hepatic function, D.) Concomitant use of monoamine oxidase inhibitors, E.) Concomitant use of reserpine or within 20 days of discontinuing reserpine
Required Medical Information	Diagnosis of chorea associated with Huntington's disease
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

THALOMID

Products Affected

- THALOMID

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Multiple myeloma that is newly diagnosed, or B.) Erythema nodosum leprosum (ENL)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, infectious disease specialist, or dermatologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TIBSOVO

Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation (as detected by an FDA-approved test), B.) Previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation (as detected by an FDA-approved test.), C.) Acute myeloid leukemia (newly-diagnosed) with susceptible isocitrate dehydrogenase-1 mutation and meets one of the following: 1.) Patient is 75 years of age or older, or 2.) Patient has comorbidities that preclude intensive induction chemotherapy, or D.) Relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation (as detected by an FDA-approved test)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hematologist, hepatologist, or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TOBI

Products Affected

- TOBI PODHALER

PA Criteria	Criteria Details
Exclusion Criteria	Known sensitivity to any aminoglycoside
Required Medical Information	Diagnosis of cystic fibrosis (confirmed by appropriate diagnostic or genetic testing) and patient has suspected or confirmed <i>Pseudomonas aeruginosa</i> infection in the lungs
Age Restrictions	6 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TOPICAL RETINOIDS

Products Affected

- *adapalene*
- *tretinoin external*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of mild to moderate acne vulgaris
Age Restrictions	PA applies to patients older than 26 years of age
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TOPICAL TESTOSTERONE

Products Affected

- *testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*
- *testosterone transdermal solution*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Carcinoma of the breast (males only), or B.) Known or suspected carcinoma of the prostate
Required Medical Information	Diagnosis of one of the following A.) Hypogonadotropic hypogonadism, or B.) Primary hypogonadism. Diagnosis of hypogonadism must be confirmed by a low-for-age serum testosterone (total or free) level defined by the normal laboratory reference value
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TOREMIFENE

Products Affected

- *toremifene citrate*

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Acquired or congenital long QT syndrome, B.) Uncorrected hypokalemia, C.) Uncorrected hypomagnesemia
Required Medical Information	Diagnosis of metastatic breast cancer and patient must have previous inadequate response or intolerance to tamoxifen
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	6 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TRELSTAR

Products Affected

- TRELSTAR MIXJECT RECONSTITUTED 11.25 MG, 22.5 MG,
INTRAMUSCULAR SUSPENSION 3.75 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of advanced prostate cancer
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	B vs D determination required per CMS guidance
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TREMFYA

Products Affected

- TREMFYA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe plaque psoriasis, B.) Active psoriatic arthritis. For moderate to severe plaque psoriasis: 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) the patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected).
Age Restrictions	18 years of age or older
Prescriber Restrictions	For PsO: Dermatologist, For PsA Dermatologist or Rheumatologist
Coverage Duration	Plan Year
Other Criteria	Only for biologic therapy-naive patients: Physician's certification stating tuberculosis (TB) negative status or negative result of a TB detection test with a reading date less than 12 months before the start of therapy or chest x ray.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PA Criteria	Criteria Details
Part B Prerequisite	No

Prior Authorization Criteria
MCS Classicare Formulary 1 - Formulary ID: 25509
Effective date: 01/01/2025 Last Updated: 09/26/2024

TRIENTINE

Products Affected

- *trientine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Wilson's disease in patients that are intolerant to penicillamine
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TRIKAFTA

Products Affected

- TRIKAFTA ORAL TABLET THERAPY PACK
- TRIKAFTA ORAL THERAPY PACK 100-50-75 & 75 MG, 80-40-60 & 59.5 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of cystic fibrosis (CF) and patient has at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to elexacaftor/tezacaftor/ivacaftor verified by an FDA-cleared CF mutation test
Age Restrictions	2 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TRUQAP

Products Affected

- TRUQAP

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with 1 or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test and, A.) patient has had disease progression following 1 or more endocrine-based regimen(s) in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy, and B.) will be used in combination with fulvestrant injection.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TUKYSA

Products Affected

- TUKYSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following: A.) advanced unresectable or metastatic HER2-positive breast cancer (including brain metastases) in patients who have received one or more prior anti-HER2-based regimens in the metastatic setting and drug is being used in combination with trastuzumab and capecitabine, or B.) unresectable or metastatic RAS wild-type, HER2-positive colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy and drug is being used in combination with trastuzumab
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TURALIO

Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Liver function tests prior to initiation.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

TYMLOS

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of osteoporosis in men or postmenopausal women and one of the following A.) osteoporotic fracture or multiple risk factors for fracture, or B.) previous trial of/or contraindication to bisphosphonate
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan year (Maximum 24 month treatment per patient lifetime)
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

UBRELVY

Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)
Required Medical Information	Diagnosis of migraine disorder with or without aura and patient has documented trial, inadequate response, or contraindication to at least 1 generic formulary triptan
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VALCHLOR

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	PA Criteria: Pending CMS Approval
Required Medical Information	PA Criteria: Pending CMS Approval
Age Restrictions	PA Criteria: Pending CMS Approval
Prescriber Restrictions	PA Criteria: Pending CMS Approval
Coverage Duration	PA Criteria: Pending CMS Approval
Other Criteria	PA Criteria: Pending CMS Approval
Indications	PA Criteria: Pending CMS Approval
Off-Label Uses	PA Criteria: Pending CMS Approval
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VALTOCO

Products Affected

- VALTOCO 20 MG DOSE

PA Criteria	Criteria Details
Exclusion Criteria	Acute narrow angle glaucoma
Required Medical Information	Diagnosis of epilepsy and documentation of use for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern.
Age Restrictions	6 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VANFLYTA

Products Affected

- VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Patient must have all of the following A.) Newly diagnosed acute myeloid leukemia with FLT3-ITD mutation, B.) Used in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, and C.) Must be enrolled in the VANFLYTA REMS program
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VENCLEXTA

Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with strong CYP3A inhibitor during the initial and titration phase in patients with CLL or SLL
Required Medical Information	Diagnosis of one of the following A.) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), or B.) Newly-diagnosed acute myeloid leukemia (AML) and used in combination with azacitidine, decitabine or low-dose cytarabine in patients 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VEOZAH

Products Affected

- VEOZAH

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of moderate to severe menopausal vasomotor symptoms (VMS) and A.) Initial treatment: The patient is experiencing 7 or more hot flashes per day and has a trial, failure or contraindication to hormonal therapy such as estradiol patch or oral conjugated estrogens, or B.) Continuing therapy: The patient has continued need for VMS treatment and experienced a reduction in VMS frequency or severity due to Veozah treatment
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VERQUVO

Products Affected

- VERQUVO

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of other soluble guanylate cyclase (sGC) stimulators
Required Medical Information	Diagnosis of chronic heart failure (HF), NYHA Class II to IV and all of the following 1.) Left ventricular ejection fraction less than 45%, 2.) Previous hospitalization for HF within 6 months or outpatient IV diuretic treatment for HF within 3 months
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VERZENIO

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer and ALL of the following: 1.) Patient is at high risk of recurrence, and 2.) Requested drug will be used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment, OR B.) Advanced or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and one of the following 1.) Used in combination with fulvestrant in a patient with disease progression following endocrine therapy, 2.) Used as monotherapy in a patient with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting, or 3.) For postmenopausal women, and men, used as initial endocrine-based treatment in combination with an aromatase inhibitor
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VIGABATRIN

Products Affected

- *vigabatrín*
- *vigadrone*
- *vigpoder*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Infantile spasms, or B.) Refractory complex partial seizures and the drug is being used as adjunctive therapy in patients who have responded inadequately to two alternative treatments
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VIJOICE

Products Affected

- VIJOICE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) in patients who require systemic therapy
Age Restrictions	2 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VITRAKVI

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic or surgically unresectable neurotrophic receptor tyrosine kinase (NTRK) gene fusion positive solid tumors without a known acquired resistance mutation and used in patients with unsatisfactory alternative treatments or who have progressed following treatment
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VIZIMPRO

Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic non-small cell lung cancer with confirmed epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VONJO

Products Affected

- VONJO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of intermediate or high-risk primary or secondary myelofibrosis in adults AND a platelet count less than $50 \times 10^9/L$
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VORICONAZOLE

Products Affected

- VORICONAZOLE INTRAVENOUS
- voriconazole oral tablet 200 mg, 50 mg
- voriconazole oral suspension reconstituted

PA Criteria	Criteria Details
Exclusion Criteria	Any of the following A.) Concomitant use of carbamazepine, CYP3A4 substrates (e.g., terfenadine, astemizole, cisapride, pimozide, or quinidine), B.) Concomitant use with high-dose ritonavir (400mg every 12 hours), C.) Concomitant use with ergot alkaloids, D.) Concomitant use with long-acting barbiturates, E.) Concomitant use with rifabutin or rifampin, F.) Concomitant use with sirolimus, or G.) Concomitant use with efavirenz at standard doses of 400mg/day or higher
Required Medical Information	Diagnosis of one of the following A.) Invasive aspergillosis, B.) Candidemia, C.) Esophageal Candidiasis, D.) Invasive candidiasis of the skin and abdomen, kidney, bladder wall, and wounds, or E.) Serious fungal infection due to <i>Scedosporium apiospermum</i> or <i>Fusarium</i> species
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist
Coverage Duration	6 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VOTRIENT

Products Affected

- VOTRIENT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Advanced renal cell carcinoma, or B.) Advanced soft tissue sarcoma and patient received at least one prior chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VOWST

Products Affected

- VOWST

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of prevention of recurrent Clostridioides difficile infection (CDI) and one of the following 1.) Patient has completed antibiotic treatment for at least 3 CDI episodes, or 2.) Previously received Vowst and both of the following A.) Treatment failure (defined as the presence of CDI diarrhea within 8 weeks of first dose of Vowst and a positive stool test for C. Difficile, and B.) Patient has not received more than one treatment course of vovst which was at least 12 days and not more than 8 weeks prior
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	30 days
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

VUMERITY

Products Affected

- VUMERITY

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsing forms of multiple sclerosis (e.g., clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, or progressive-relapsing MS), or B.) Patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

WELIREG

Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Von Hippel-Lindau (VHL) disease and therapy is required for any of the following disease associated tumors that do not require immediate surgery 1.) Renal cell carcinoma (RCC), 2.) Central nervous system (CNS) hemangioblastoma, or 3.) Pancreatic neuroendocrine tumor (pNET), or B.) Advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand 1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XALKORI

Products Affected

- XALKORI ORAL CAPSULE
- XALKORI ORAL CAPSULE SPRINKLE 150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS1-positive as detected by an FDA-approved test, B.) Relapsed or refractory systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test, or C.) Unresectable, recurrent, or refractory inflammatory myofibroblastic tumors that are anaplastic lymphoma kinase (ALK)-positive
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XCOPRI

Products Affected

- XCOPRI (250 MG DAILY DOSE)
- XCOPRI (350 MG DAILY DOSE)
- XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 25 MG, 50 MG
- XCOPRI ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	Familial short QT syndrome
Required Medical Information	Diagnosis of partial-onset seizures
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XDEMVY

Products Affected

- XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Demodex blepharitis
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	12 months
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XELJANZ

Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ ORAL TABLET 10 MG, 5 MG
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Moderate to severe rheumatoid arthritis (RA), B.) Active psoriatic arthritis, C.) Moderate to severe ulcerative colitis (UC), D.) Polyarticular course juvenile idiopathic arthritis (pcJIA), or E.) Active ankylosing spondylitis. Screening for latent tuberculosis infection is required prior to initiation of treatment.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Screening for latent tuberculosis infection is required prior to initiation of treatment
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XERMELO

Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of carcinoid syndrome diarrhea and both of the following 1.) Diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g., octreotide, lanreotide) for at least 3 months, and 2.) Used in combination with SSA therapy
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist
Coverage Duration	Plan year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XGEVA

Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	Hypocalcemia (calcium less than 8.0 mg/dL)
Required Medical Information	Diagnosis of one of the following A.) Bone metastases from a solid tumor, used for the prevention of skeletal related events and must have an inadequate treatment response, adverse event, or contraindication to zoledronic acid, B.) Multiple myeloma, used for the prevention of skeletal related events and must have an inadequate treatment response, adverse event, or contraindication to zoledronic acid, C.) Hypercalcemia of malignancy refractory to bisphosphonate therapy and must have an inadequate treatment response, adverse event, or contraindication to zoledronic acid, or D.) Giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	B vs D determination required per CMS guidance
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	Yes

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XOLAIR

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chronic idiopathic urticaria in patients who remain symptomatic despite H1 antihistamine therapy for patients 12 years of age and older, B.) Moderate to severe persistent asthma in patients 6 years of age or older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms are inadequately controlled with inhaled corticosteroids or Dupixent, C.) Nasal polyps in patients 18 years of age or older with inadequate response to nasal corticosteroids, or D.) Reduction of allergic reactions (type I), including anaphylaxis, that may occur with accidental exposure to 1 or more foods in with IgE-mediated food allergy and is being used in conjunction with food allergen avoidance in patient 1 year of age or older
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with an allergist, dermatologist, immunologist, otolaryngologist, or pulmonologist
Coverage Duration	Initial: 6 months, Renewal: Plan Year
Other Criteria	B vs D coverage determination per CMS guidelines
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XOSPATA

Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an Oncologist or Hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XPOVIO

Products Affected

- XPOVIO (100 MG ONCE WEEKLY)
- XPOVIO (40 MG ONCE WEEKLY)
- XPOVIO (40 MG TWICE WEEKLY)
- XPOVIO (60 MG ONCE WEEKLY)
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Relapsed or refractory multiple myeloma being used in combination with dexamethasone in a patient who has received at least 4 prior therapies and is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody, B.) Multiple myeloma being used in combination with bortezomib and dexamethasone in a patient who has received at least 1 prior therapy, C.) Relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, or D.) Relapsed or refractory DLBCL arising from follicular lymphoma and patient has received at least 2 lines of systemic therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XTANDI

Products Affected

- XTANDI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Castration-resistant prostate cancer (CRPC), B.) Metastatic, castration-sensitive prostate cancer (mCSPC). For treatment of CRPC and mCSPC, one of the following applies 1.) Used in combination with a gonadotropin-releasing hormone (GnRH) analog or 2) Patient has received bilateral orchiectomy, or C.) Nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

YONSA

Products Affected

- YONSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of metastatic, castration-resistant prostate cancer (mCRPC) and used in combination with methylprednisolone. For treatment of mCRPC, one of the following applies: 1.) Used in combination with a gonadotropin-releasing hormone (GnRH) analog or 2) Patient has received bilateral orchiectomy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ZARXIO

Products Affected

- ZARXIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Chemotherapy induced febrile neutropenia (prophylaxis), B.) Severe chronic neutropenia, C.) Patient is undergoing autologous peripheral-blood progenitor cell transplant to mobilize progenitor cells for collection by leukapheresis, or D.) Hematopoietic subsyndrome of acute radiation syndrome (H-ARS)
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ZEJULA

Products Affected

- ZEJULA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of Advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and used as maintenance therapy in a patient who is in a complete or partial response to platinum-based chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ZELBORAF

Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of one of the following A.) Unresectable or metastatic melanoma and patient has positive BRAF-V600E mutation documented by an FDA-approved test, or B.) Erdheim-Chester disease and patient has documented BRAF V600 mutation
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ZIEXTENZO

Products Affected

- ZIEXTENZO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of a non-myeloid malignancy and drug is being used as prophylaxis for chemotherapy-induced neutropenia
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ZOLINZA

Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of primary cutaneous T-cell lymphoma (CTCL) in patients who have progressive, persistent or recurrent disease on or following two systemic therapies (e.g., bexarotene, romidepsin, etc)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ZTALMY

Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ZURZUVAE

Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of postpartum depression
Age Restrictions	18 years of age and older
Prescriber Restrictions	None
Coverage Duration	14 days
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ZYDELIG

Products Affected

- ZYDELIG ORAL TABLET 100 MG, 150 MG

PA Criteria	Criteria Details
Exclusion Criteria	History of toxic epidermal necrosis with any drug
Required Medical Information	Diagnosis of Chronic lymphocytic leukemia, used in combination with rituximab and patient has relapsed on at least one prior therapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

ZYKADIA

Products Affected

- ZYKADIA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PART B VERSUS PART D

Products Affected

- ABILIFY ASIMTUFII
INTRAMUSCULAR PREFILLED
SYRINGE 720 MG/2.4ML, 960
MG/3.2ML
- ABILIFY MAINTENA
INTRAMUSCULAR PREFILLED
SYRINGE 300 MG, 400 MG
- ABILIFY MAINTENA
INTRAMUSCULAR SUSPENSION
RECONSTITUTED ER 300 MG, 400 MG
- *acetylcysteine inhalation solution 10 %, 20 %*
- *acyclovir sodium intravenous solution 50 mg/ml*
- *albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml*
- *amphotericin b intravenous solution reconstituted 50 mg*
- *amphotericin b liposome intravenous suspension reconstituted 50 mg*
- *ampicillin sodium injection solution reconstituted 1 gm, 125 mg*
- *aprepitant oral capsule 125 mg, 40 mg, 80 & 125 mg, 80 mg*
- *azathioprine oral tablet 50 mg*
- *azithromycin intravenous solution reconstituted 500 mg*
- *budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml*
- *calcitonin (salmon) nasal solution 200 unit/act*
- *calcitriol oral capsule 0.25 mcg, 0.5 mcg*
- *calcitriol oral solution 1 mcg/ml*
- *cefoxitin sodium intravenous solution reconstituted 1 gm, 10 gm, 2 gm*
- *cefuroxime sodium injection solution reconstituted 750 mg*
- *cefuroxime sodium intravenous solution reconstituted 1.5 gm*
- *cinacalcet hcl oral tablet 30 mg, 60 mg, 90 mg*
- CINRYZE INTRAVENOUS SOLUTION
RECONSTITUTED 500 UNIT
- *ciprofloxacin in d5w intravenous solution 200 mg/100ml*
- *clindamycin phosphate injection solution 900 mg/6ml*
- CLINIMIX/DEXTROSE (4.25/5)
INTRAVENOUS SOLUTION 4.25 %
- CLINIMIX/DEXTROSE (5/15)
INTRAVENOUS SOLUTION 5 %
- CLINIMIX/DEXTROSE (5/20)
INTRAVENOUS SOLUTION 5 %
- *colistimethate sodium (cba) injection solution reconstituted 150 mg*
- *cromolyn sodium inhalation nebulization solution 20 mg/2ml*
- CYCLOPHOSPHAMIDE ORAL
CAPSULE 25 MG
- *cyclophosphamide oral capsule 50 mg*
- *cyclophosphamide oral tablet 25 mg*
- CYCLOPHOSPHAMIDE ORAL
TABLET 50 MG
- *cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg*
- *cyclosporine modified oral solution 100 mg/ml*
- *cyclosporine oral capsule 100 mg, 25 mg*
- *dextrose intravenous solution 10 %, 5 %*
- DEXTROSE-SODIUM CHLORIDE
INTRAVENOUS SOLUTION 10-0.2 %, 10-0.45 %, 2.5-0.45 %
- *doxy 100 intravenous solution reconstituted 100 mg*

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

- ENGERIX-B INJECTION SUSPENSION 20 MCG/ML
- ENGERIX-B INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/0.5ML, 20 MCG/ML
- ENVARUSUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG
- *everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg*
- *fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%, 400-0.9 mg/200ml-%*
- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA INTRAVENOUS SOLUTION RECONSTITUTED 10 GM, 5 GM
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- *granisetron hcl oral tablet 1 mg*
- *heparin sodium (porcine) injection solution 10000 unit/ml, 20000 unit/ml, 5000 unit/ml*
- HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 20 MCG/0.5ML
- IMOVAX RABIES INTRAMUSCULAR SUSPENSION RECONSTITUTED 2.5 UNIT/ML
- *ipratropium bromide inhalation solution 0.02 %*
- *ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml*
- ISOLYTE-P IN D5W INTRAVENOUS SOLUTION
- ISOLYTE-S PH 7.4 INTRAVENOUS SOLUTION
- JYLAMVO ORAL SOLUTION 2 MG/ML
- *kcl in dextrose-nacl intravenous solution 10-5-0.45 meq/l-%-%, 20-5-0.2 meq/l-%-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-%, 30-5-0.45 meq/l-%-%, 40-5-0.45 meq/l-%-%*
- KCL IN DEXTROSE-NACL INTRAVENOUS SOLUTION 40-5-0.9 MEQ/L-%-%
- KCL-LACTATED RINGERS-D5W INTRAVENOUS SOLUTION 20 MEQ/L
- *methotrexate sodium (pf) injection solution 50 mg/2ml*
- *methotrexate sodium injection solution 50 mg/2ml*
- *metronidazole intravenous solution 500 mg/100ml*
- *multiple electro type 1 ph 5.5 intravenous solution*
- *mycophenolate mofetil oral capsule 250 mg*
- *mycophenolate mofetil oral suspension reconstituted 200 mg/ml*
- *mycophenolate mofetil oral tablet 500 mg*
- *mycophenolate sodium oral tablet delayed release 180 mg, 360 mg*
- NUTRILIPID INTRAVENOUS EMULSION 20 %
- *ondansetron hcl oral solution 4 mg/5ml*
- *ondansetron hcl oral tablet 4 mg, 8 mg*
- *ondansetron oral tablet dispersible 4 mg, 8 mg*
- *paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg*
- *penicillin g potassium injection solution reconstituted 20000000 unit*
- *penicillin g sodium injection solution reconstituted 5000000 unit*
- *pentamidine isethionate inhalation solution reconstituted 300 mg*

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

- *pentamidine isethionate injection solution reconstituted 300 mg*
- PERSERIS SUBCUTANEOUS PREFILLED SYRINGE 120 MG, 90 MG
- PLASMA-LYTE A INTRAVENOUS SOLUTION
- POTASSIUM CHLORIDE IN NACL INTRAVENOUS SOLUTION 20-0.45 MEQ/L-%, 40-0.9 MEQ/L-%
- *potassium chloride in nacl intravenous solution 20-0.9 meq/l-%*
- POTASSIUM CHLORIDE INTRAVENOUS SOLUTION 10 MEQ/100ML, 20 MEQ/100ML, 40 MEQ/100ML
- *potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml)*
- *potassium cl in dextrose 5% intravenous solution 20 meq/l*
- PREHEVBRIO INTRAMUSCULAR SUSPENSION 10 MCG/ML
- PROGRAF ORAL PACKET 0.2 MG, 1 MG
- PROLASTIN-C INTRAVENOUS SOLUTION 1000 MG/20ML
- RABAVERT INTRAMUSCULAR SUSPENSION RECONSTITUTED
- RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5ML
- RECOMBIVAX HB INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/ML, 5 MCG/0.5ML
- RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 12.5 MG, 25 MG, 37.5 MG, 50 MG
- *sirolimus oral solution 1 mg/ml*
- *sirolimus oral tablet 0.5 mg, 1 mg, 2 mg*
- *tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg*
- TEFLARO INTRAVENOUS SOLUTION RECONSTITUTED 400 MG, 600 MG
- TIGECYCLINE INTRAVENOUS SOLUTION RECONSTITUTED 50 MG
- *tobramycin inhalation nebulization solution 300 mg/5ml*
- *tobramycin sulfate injection solution 10 mg/ml, 80 mg/2ml*
- TPN ELECTROLYTES INTRAVENOUS CONCENTRATE
- TRAVASOL INTRAVENOUS SOLUTION 10 %
- TROPHAMINE INTRAVENOUS SOLUTION 10 %
- *ziprasidone mesylate intramuscular solution reconstituted 20 mg*

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

Alphabetical Listing

A

ABILIFY ASIMTUFII INTRAMUSCULAR PREFILLED SYRINGE 720 MG/2.4ML, 960 MG/3.2ML	295	alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg.....	100, 101
ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300 MG, 400 MG	295	ALUNBRIG	12
ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300 MG, 400 MG	295	ambrisentan	13
abiraterone acetate oral tablet 250 mg, 500 mg.....	1	AMJEVITA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.4ML, 80 MG/0.8ML	14, 15
acetylcysteine inhalation solution 10 %, 20 %	295	AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	14, 15
acitretin.....	2	AMJEVITA-PED 15KG TO <30KG	14, 15
ACTEMRA.....	3	amphotericin b intravenous solution reconstituted 50 mg	295
ACTEMRA ACTPEN	3	amphotericin b liposome intravenous suspension reconstituted 50 mg ...	295
ACTIMMUNE	4	ampicillin sodium injection solution reconstituted 1 gm, 125 mg	295
acyclovir sodium intravenous solution 50 mg/ml.....	295	aprepitant oral capsule 125 mg, 40 mg, 80 & 125 mg, 80 mg	295
adalimumab-adbm (2 pen)	5, 6	APTIOM	16
adalimumab-adbm (2 syringe) subcutaneous prefilled syringe kit 10 mg/0.2ml, 20 mg/0.4ml, 40 mg/0.8ml	5, 6	ARCALYST	17
adalimumab-adbm(cd/uc/hs str)	5, 6	ARIKAYCE	18
adalimumab-adbm(ps/uv starter)	5, 6	armodafinil.....	44
adapalene	245	AUGTYRO	20
adefovir dipivoxil.....	91	AUSTEDO.....	21
ADEMPAS.....	7	AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG	21
AKEEGA	9	AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE THERAPY PACK 12 & 18 & 24 & 30 MG, 6 & 12 & 24 MG.....	21
albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml	295	AUVELITY	22
ALECENSA	10	AYVAKIT	23
alosetron hcl.....	11	azathioprine oral tablet 50 mg	295
		azithromycin intravenous solution reconstituted 500 mg	295

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

B

BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG	24
BARACLUDE	91
BENLYSTA	26
benztropine mesylate	99
BESREMI	27
bexarotene	28, 29
bosentan	30
BOSULIF ORAL CAPSULE 100 MG, 500 MG	31
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG	31
BRAFTOVI	32
BRIVIACT.....	33
BRONCHITOL.....	34
BRUKINSA.....	35
budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml	295
butalbital-acetaminophen	93
butalbital-apap-caffeine	93
BYDUREON BCISE	89

C

CABOMETYX.....	36
calcitonin (salmon) nasal solution 200 unit/act	295
calcitriol oral capsule 0.25 mcg, 0.5 mcg	295
calcitriol oral solution 1 mcg/ml	295
CALQUENCE	37
CAMZYOS	38
CAPLYTA.....	19
CAPRELSA ORAL TABLET 100 MG, 300 MG	39
carglumic acid	40
CAYSTON	41
cefoxitin sodium intravenous solution reconstituted 1 gm, 10 gm, 2 gm ..	295
cefuroxime sodium injection solution reconstituted 750 mg	295
cefuroxime sodium intravenous solution reconstituted 1.5 gm	295

chlordiazepoxide hcl.....	100, 101
chlordiazepoxide-amitriptyline	97
chlordiazepoxide-clidinium	95
CIMZIA	42
CIMZIA (2 SYRINGE).....	42
cinacalcet hcl oral tablet 30 mg, 60 mg, 90 mg.....	295
CINRYZE INTRAVENOUS SOLUTION RECONSTITUTED 500 UNIT	295
ciprofloxacin in d5w intravenous solution 200 mg/100ml.....	295
clindamycin phosphate injection solution 900 mg/6ml.....	295
CLINIMIX/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25 %	295
CLINIMIX/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5 % .	295
CLINIMIX/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5 % .	295
clobazam oral suspension.....	43
clobazam oral tablet	43
clonazepam oral tablet 0.5 mg, 1 mg, 2 mg.....	104, 105
clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg	104, 105
clorazepate dipotassium.....	104, 105
colistimethate sodium (cba) injection solution reconstituted 150 mg.....	295
COMETRIQ (100 MG DAILY DOSE) .	45
COMETRIQ (140 MG DAILY DOSE) .	45
COMETRIQ (60 MG DAILY DOSE) ...	45
COPIKTRA.....	46
CORLANOR.....	47
COSENTYX	48
COSENTYX (300 MG DOSE)	48
COSENTYX SENSOREADY (300 MG)	48
COSENTYX UNOREADY	48
COTELLIC.....	49

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

cromolyn sodium inhalation nebulization solution 20 mg/2ml.....	295
cyclobenzaprine hcl.....	107
CYCLOPHOSPHAMIDE ORAL	
CAPSULE 25 MG	295
cyclophosphamide oral capsule 50 mg	295
cyclophosphamide oral tablet 25 mg	295
CYCLOPHOSPHAMIDE ORAL TABLET 50 MG	295
cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg.....	295
cyclosporine modified oral solution 100 mg/ml.....	295
cyclosporine oral capsule 100 mg, 25 mg.....	295
CYSTAGON	50
D	
dalfampridine er	51
DAURISMO	52
DAYBUE	53
deferasirox	54
deferiprone	55
dextrose intravenous solution 10 %, 5 %	295
DEXTROSE-SODIUM CHLORIDE INTRAVENOUS SOLUTION 10-0.2 %, 10-0.45 %, 2.5-0.45 %	295
DIACOMIT	56
diazepam intensol	104, 105
diazepam oral solution	104, 105
diazepam oral tablet	104, 105
diclofenac epolamine.....	57
DIGOXIN ORAL SOLUTION	94
digoxin oral tablet 250 mcg	94
dimethyl fumarate.....	58
dimethyl fumarate starter pack	58
doxy 100 intravenous solution reconstituted 100 mg	295
dronabinol	59
droxidopa	60
DUPIXENT	61, 62

E	
ELIGARD SUBCUTANEOUS KIT 22.5 MG, 30 MG, 45 MG, 7.5 MG	143
EMGALITY	63
EMGALITY (300 MG DOSE)	63
EMSAM	64
ENBREL	65, 66
ENBREL MINI	65, 66
ENBREL SURECLICK	65, 66
ENGERIX-B INJECTION SUSPENSION 20 MCG/ML	296
ENGERIX-B INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/0.5ML, 20 MCG/ML	296
ENSPRYNG	67
entecavir.....	91
ENVARUSUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG	296
EPIDIOLEX	68
ergoloid mesylates	96
ERIVEDGE	70
ERLEADA	71
erlotinib hcl	72
estazolam.....	100, 101
everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg.....	296
everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg.....	8
everolimus oral tablet soluble 2 mg, 3 mg, 5 mg.....	73
EVRYSDI	74
F	
FANAPT	19
FANAPT TITRATION PACK	19
FASENRA	75
FASENRA PEN	75
febuxostat.....	76
fentanyl citrate	77
FILSPARI	78
FIRMAGON	79
FIRMAGON (240 MG DOSE)	79

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%, 400-0.9 mg/200ml-%	296
FOTIVDA.....	80
FRUZAQLA.....	81
FULPHILA.....	82
FYCOMPA.....	83
G	
GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML.....	296
GAMMAGARD S/D LESS IGA INTRAVENOUS SOLUTION RECONSTITUTED 10 GM, 5 GM.	296
GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML.....	296
GAMUNEX-C INJECTION SOLUTION 1 GM/10ML.....	296
GAVRETO.....	84
gefitinib.....	85
GILOTRIF.....	86
glatiramer acetate.....	87
GLEOSTINE.....	88
granisetron hcl oral tablet 1 mg.....	296
guanfacine hcl er.....	102
H	
heparin sodium (porcine) injection solution 10000 unit/ml, 20000 unit/ml, 5000 unit/ml.....	296
HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 20 MCG/0.5ML.....	296
hydroxyzine hcl.....	98
hydroxyzine pamoate.....	98
HYFTOR.....	108
I	
IBRANCE.....	109
icatibant acetate.....	110
ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG.....	111

IDHIFA ORAL TABLET 100 MG, 50 MG	112
imatinib mesylate oral tablet 100 mg, 400 mg.....	113
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG.....	114
IMBRUVICA ORAL SUSPENSION..	114
IMBRUVICA ORAL TABLET.....	114
IMOVAX RABIES INTRAMUSCULAR SUSPENSION RECONSTITUTED 2.5 UNIT/ML.....	296
IMPAVIDO.....	115
INCRELEX.....	116
INLYTA.....	118
INQOVI.....	119
INREBIC.....	120
INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1092 MG/3.5ML, 1560 MG/5ML.....	121
INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML, 156 MG/ML, 234 MG/1.5ML, 39 MG/0.25ML, 78 MG/0.5ML.....	122, 123
INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML.....	124
ipratropium bromide inhalation solution 0.02 %.....	296
ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml.....	296
ISOLYTE-P IN D5W INTRAVENOUS SOLUTION.....	296
ISOLYTE-S PH 7.4 INTRAVENOUS SOLUTION.....	296
itraconazole.....	125
ivabradine hcl.....	126
ivermectin.....	127

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

IWILFIN	128	LENVIMA (8 MG DAILY DOSE)	141
J		LEUKINE	142
JAKAFI	129	leuprolide acetate	143
JAYPIRCA ORAL TABLET 100 MG, 50 MG	130	LEUPROLIDE ACETATE (3 MONTH)	143
JOENJA	131	l-glutamine	144
JYLAMVO ORAL SOLUTION 2 MG/ML	296	lidocaine external ointment.....	145
K		lidocaine hcl	145
KALYDECO	132	linezolid intravenous.....	146
kcl in dextrose-nacl intravenous solution 10-5-0.45 meq/l-%-%, 20-5-0.2 meq/l- %-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-%, 30-5-0.45 meq/l-%-%, 40- 5-0.45 meq/l-%-%	296	linezolid oral suspension reconstituted	146
KCL IN DEXTROSE-NACL INTRAVENOUS SOLUTION 40-5-0.9 MEQ/L-%-%.....	296	linezolid oral tablet.....	146
KCL-LACTATED RINGERS-D5W INTRAVENOUS SOLUTION 20 MEQ/L	296	LIVTENCITY	147
KERENDIA.....	133	LONSURF	148
KISQALI (200 MG DOSE)	134	lorazepam	104, 105
KISQALI (400 MG DOSE)	134	lorazepam intensol	104, 105
KISQALI (600 MG DOSE)	134	LORBRENA ORAL TABLET 100 MG, 25 MG.....	149
KISQALI FEMARA (200 MG DOSE)	135	LUMAKRAS ORAL TABLET 120 MG, 320 MG	150
KISQALI FEMARA (400 MG DOSE)	135	LUPRON DEPOT (1-MONTH)	143
KISQALI FEMARA (600 MG DOSE)	135	LUPRON DEPOT (3-MONTH)	143
KORLYM	136	LUPRON DEPOT (4-MONTH)	143
KOSELUGO	137	LUPRON DEPOT (6-MONTH)	143
KRAZATI	138	LUPRON DEPOT-PED (1-MONTH)	143
L		LUPRON DEPOT-PED (3-MONTH)	143
lapatinib ditosylate.....	139	LUPRON DEPOT-PED (6-MONTH)	143
ledipasvir-sofosbuvir.....	92	LYBALVI.....	19
lenalidomide	140	LYNPARZA	151, 152
LENVIMA (10 MG DAILY DOSE)	141	LYTGOBI (12 MG DAILY DOSE)	153
LENVIMA (12 MG DAILY DOSE)	141	LYTGOBI (16 MG DAILY DOSE)	153
LENVIMA (14 MG DAILY DOSE)	141	LYTGOBI (20 MG DAILY DOSE)	153
LENVIMA (18 MG DAILY DOSE)	141	M	
LENVIMA (20 MG DAILY DOSE)	141	MATULANE.....	154
LENVIMA (24 MG DAILY DOSE)	141	MAVYRET	92
LENVIMA (4 MG DAILY DOSE)	141	MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG	155
		MAYZENT STARTER PACK.....	155
		megestrol acetate.....	103
		MEKINIST	156
		MEKTOVI	157

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

methotrexate sodium (pf) injection solution 50 mg/2ml.....	296	ondansetron hcl oral tablet 4 mg, 8 mg	296
methotrexate sodium injection solution 50 mg/2ml.....	296	ondansetron oral tablet dispersible 4 mg, 8 mg.....	296
metronidazole intravenous solution 500 mg/100ml.....	296	ONUREG	172
mifepristone.....	158	OPSUMIT	173
miglustat.....	159	OPSYNVI	174
modafinil.....	44	ORENCIA CLICKJECT	175
MOUNJARO.....	89	ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MG/ML, 50 MG/0.4ML, 87.5 MG/0.7ML.....	175
multiple electro type 1 ph 5.5 intravenous solution.....	296	ORGOVYX	176
mycophenolate mofetil oral capsule 250 mg.....	296	ORKAMBI.....	177
mycophenolate mofetil oral suspension reconstituted 200 mg/ml	296	orphenadrine citrate er	107
mycophenolate mofetil oral tablet 500 mg.....	296	ORSERDU ORAL TABLET 345 MG, 86 MG.....	178
mycophenolate sodium oral tablet delayed release 180 mg, 360 mg .	296	OTEZLA ORAL TABLET	179
N		OTEZLA ORAL TABLET THERAPY PACK.....	179
NAYZILAM	160	OZEMPIC (0.25 OR 0.5 MG/DOSE) ..	89
NERLYNX	161	OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN- INJECTOR 2 MG/1.5ML, 4 MG/3ML	89
NINLARO	162	OZEMPIC (2 MG/DOSE).....	89
NUBEQA	163	P	
NUEDEXTA.....	164	PANRETIN	180
NUPLAZID	165	paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg.....	296
NUTRILIPID INTRAVENOUS EMULSION 20 %.....	296	pazopanib hcl	181
O		PEGASYS	182
octreotide acetate.....	166	PEMAZYRE	183
ODOMZO	167	penicillamine	184
OFEV	168	penicillin g potassium injection solution reconstituted 2000000 unit	296
OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG.....	169	penicillin g sodium injection solution reconstituted 5000000 unit	296
OJEMDA ORAL SUSPENSION RECONSTITUTED	170	pentamidine isethionate inhalation solution reconstituted 300 mg.....	296
OJEMDA ORAL TABLET	170	pentamidine isethionate injection solution reconstituted 300 mg.....	297
OJJAARA	171		
OMNITROPE	90		
ondansetron hcl oral solution 4 mg/5ml	296		

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

PERSERIS SUBCUTANEOUS	
PREFILLED SYRINGE 120 MG, 90	
MG.....	297
PIQRAY (200 MG DAILY DOSE)	185
PIQRAY (250 MG DAILY DOSE)	185
PIQRAY (300 MG DAILY DOSE)	185
pirfenidone	186
PLASMA-LYTE A INTRAVENOUS	
SOLUTION	297
POMALYST.....	187
posaconazole.....	188
POTASSIUM CHLORIDE IN NACL	
INTRAVENOUS SOLUTION 20-0.45	
MEQ/L-%, 40-0.9 MEQ/L-%	297
potassium chloride in nacl intravenous	
solution 20-0.9 meq/l-%.....	297
POTASSIUM CHLORIDE	
INTRAVENOUS SOLUTION 10	
MEQ/100ML, 20 MEQ/100ML, 40	
MEQ/100ML	297
potassium chloride intravenous solution	
2 meq/ml, 2 meq/ml (20 ml)	297
potassium cl in dextrose 5% intravenous	
solution 20 meq/l.....	297
PREHEVBRIO INTRAMUSCULAR	
SUSPENSION 10 MCG/ML.....	297
PREVYMIS.....	189
PROGRAF ORAL PACKET 0.2 MG, 1	
MG.....	297
PROLASTIN-C INTRAVENOUS	
SOLUTION 1000 MG/20ML.....	297
PROLIA.....	190, 191
PROMACTA ORAL PACKET 12.5 MG,	
25 MG.....	192
PROMACTA ORAL TABLET.....	192
promethazine hcl.....	98
promethegan	98
PULMOZYME	193
PURIXAN	194
pyrimethamine.....	195
Q	
QINLOCK.....	196

quinine sulfate	197
R	
RABAVERT INTRAMUSCULAR	
SUSPENSION RECONSTITUTED	
.....	297
RAVICTI.....	198
RECOMBIVAX HB INJECTION	
SUSPENSION 10 MCG/ML, 40	
MCG/ML, 5 MCG/0.5ML	297
RECOMBIVAX HB INJECTION	
SUSPENSION PREFILLED	
SYRINGE 10 MCG/ML, 5 MCG/0.5ML	
.....	297
REGANEX	199
REPATHA	200
REPATHA PUSHTRONEX SYSTEM	
.....	200
REPATHA SURECLICK.....	200
RETACRIT	69
RETEVMO ORAL CAPSULE 40 MG, 80	
MG.....	201
RETEVMO ORAL TABLET 120 MG,	
160 MG, 40 MG, 80 MG	201
REVLIMID	202
REXULTI.....	19
REZLIDHIA	203
REZUROCK	204
riluzole.....	205
RINVOQ.....	206
RINVOQ LQ	207
RISPERDAL CONSTA	
INTRAMUSCULAR SUSPENSION	
RECONSTITUTED ER 12.5 MG, 25	
MG, 37.5 MG, 50 MG	297
RIVFLOZA SUBCUTANEOUS	
SOLUTION	208
RIVFLOZA SUBCUTANEOUS	
SOLUTION PREFILLED SYRINGE	
128 MG/0.8ML, 160 MG/ML	208
ROZLYTREK ORAL CAPSULE 100	
MG, 200 MG	209
ROZLYTREK ORAL PACKET.....	209

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

RUBRACA.....	210	SYMPAZAN	43
rufinamide oral suspension	211	SYNAREL	229
rufinamide oral tablet.....	25	T	
RYBELSUS	89	TABRECTA	230
RYDAPT.....	212	tacrolimus oral capsule 0.5 mg, 1 mg, 5	
S		mg.....	297
sapropterin dihydrochloride	213	tadalafil.....	231
SCEMBLIX	214	TAFINLAR.....	232
SECUADO	19	TAGRISSE.....	233
SIGNIFOR.....	215	TALZENNA	234
sildenafil citrate oral tablet 20 mg.....	216	TASIGNA	235
sirolimus oral solution 1 mg/ml	297	TAVNEOS	236
sirolimus oral tablet 0.5 mg, 1 mg, 2 mg		tazarotene external cream.....	237
.....	297	tazarotene external gel.....	237
SIRTURO	217	TAZORAC	237
SKYRIZI (150 MG DOSE)	218	TAZVERIK.....	238
SKYRIZI PEN.....	218	TEFLARO INTRAVENOUS SOLUTION	
SKYRIZI SUBCUTANEOUS SOLUTION		RECONSTITUTED 400 MG, 600 MG	
CARTRIDGE 180 MG/1.2ML, 360		297
MG/2.4ML.....	218	temazepam	100, 101
SKYRIZI SUBCUTANEOUS SOLUTION		TEPMETKO	239
PREFILLED SYRINGE	218	TERIPARATIDE (RECOMBINANT) .	240
sodium oxybate	219	testosterone cypionate	117
sofosbuvir-velpatasvir.....	92	testosterone enanthate.....	117
SOLTAMOX	220	testosterone transdermal gel 10 mg/act	
SOMAVERT SUBCUTANEOUS		(2%), 12.5 mg/act (1%), 20.25	
SOLUTION RECONSTITUTED 10		mg/1.25gm (1.62%), 20.25 mg/act	
MG, 15 MG, 20 MG, 25 MG, 30 MG		(1.62%), 25 mg/2.5gm (1%), 40.5	
.....	221	mg/2.5gm (1.62%), 50 mg/5gm (1%)	
sorafenib tosylate	222	246
SPRYCEL ORAL TABLET 100 MG, 140		testosterone transdermal solution	246
MG, 20 MG, 50 MG, 70 MG, 80 MG		tetrabenazine oral tablet 12.5 mg, 25 mg	
.....	223	241
STELARA SUBCUTANEOUS		THALOMID.....	242
SOLUTION	224, 225	TIBSOVO	243
STELARA SUBCUTANEOUS		TIGECYCLINE INTRAVENOUS	
SOLUTION PREFILLED SYRINGE		SOLUTION RECONSTITUTED 50	
45 MG/0.5ML, 90 MG/ML	224, 225	MG.....	297
STIVARGA.....	226	TOBI PODHALER	244
sunitinib malate	227	tobramycin inhalation nebulization	
SYMLINPEN 120	228	solution 300 mg/5ml.....	297
SYMLINPEN 60	228		

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

tobramycin sulfate injection solution 10 mg/ml, 80 mg/2ml	297	vigpoder	265
toremifene citrate	247	VIJOICE	266
TPN ELECTROLYTES INTRAVENOUS CONCENTRATE	297	VITRAKVI ORAL CAPSULE 100 MG, 25 MG	267
TRAVASOL INTRAVENOUS SOLUTION 10 %	297	VITRAKVI ORAL SOLUTION.....	267
TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25 MG, 22.5 MG, 3.75 MG	248	VIZIMPRO	268
TREMFYA	249, 250	VONJO.....	269
tretinoin external.....	245	VORICONAZOLE INTRAVENOUS..	270
trientine hcl.....	251	voriconazole oral suspension reconstituted	270
trihexyphenidyl hcl.....	99	voriconazole oral tablet 200 mg, 50 mg	270
TRIKAFTA ORAL TABLET THERAPY PACK.....	252	VOTRIENT	271
TRIKAFTA ORAL THERAPY PACK 100-50-75 & 75 MG, 80-40-60 & 59.5 MG	252	VOWST	272
TROPHAMINE INTRAVENOUS SOLUTION 10 %	297	VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG	19
TRULICITY.....	89	VUMERITY.....	273
TRUQAP	253	W	
TUKYSA.....	254	WELIREG.....	274
TURALIO.....	255	X	
TYMLOS	256	XALKORI ORAL CAPSULE	275
U		XALKORI ORAL CAPSULE SPRINKLE 150 MG, 20 MG, 50 MG	275
UBRELVY	257	XCOPRI (250 MG DAILY DOSE).....	276
V		XCOPRI (350 MG DAILY DOSE).....	276
VALCHLOR.....	258	XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 25 MG, 50 MG.....	276
VALTOCO 20 MG DOSE	259	XCOPRI ORAL TABLET THERAPY PACK.....	276
VANFLYTA.....	260	XDEMVY	277
VEMLIDY	91	XELJANZ ORAL SOLUTION	278
VENCLEXTA.....	261	XELJANZ ORAL TABLET 10 MG, 5 MG	278
VENCLEXTA STARTING PACK	261	XELJANZ XR	278
VEOZAH	262	XERMELO.....	279
VERQUVO	263	XGEVA.....	280
VERSACLOZ	19	XOLAIR	281
VERZENIO.....	264	XOSPATA	282
vigabatrin.....	265	XPOVIO (100 MG ONCE WEEKLY)	283
vigadrone	265	XPOVIO (40 MG ONCE WEEKLY) ..	283
		XPOVIO (40 MG TWICE WEEKLY) ..	283
		XPOVIO (60 MG ONCE WEEKLY) ..	283

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024

XPOVIO (60 MG TWICE WEEKLY) .	283	ZIEXTENZO	289
XPOVIO (80 MG ONCE WEEKLY) ..	283	ziprasidone mesylate intramuscular	
XPOVIO (80 MG TWICE WEEKLY) .	283	solution reconstituted 20 mg	297
XTANDI	284	ZOLINZA	290
Y		zolpidem tartrate	106
YONSA.....	285	ZTALMY	291
Z		ZURZUVAE ORAL CAPSULE 20 MG,	
zaleplon.....	106	25 MG, 30 MG	292
ZARXIO.....	286	ZYDELIG ORAL TABLET 100 MG, 150	
ZEJULA.....	287	MG.....	293
ZELBORAF	288	ZYKADIA.....	294

Prior Authorization Criteria

MCS Classicare Formulary 1 - Formulary ID: 25509

Effective date: 01/01/2025 Last Updated: 09/26/2024